{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:19:19Z","timestamp":1793506759846,"version":"4.5.0"},"reference-count":269,"publisher":"Walter de Gruyter GmbH","issue":"8","funder":[{"name":"Long Term Research Grant Scheme (LRGS), Ministry of Higher Education, Malaysia","award":["LRGS\/1\/2019\/SYUC\/02\/1\/5"],"award-info":[{"award-number":["LRGS\/1\/2019\/SYUC\/02\/1\/5"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Biomarkers are necessary tools to validate the diagnosis of Alzheimer\u2019s and Parkinson\u2019s diseases (AD and PD), especially when clinical symptoms are less apparent in the early stages of diseases. Current biomarkers used in clinical practice rely on brain imaging and cerebrospinal fluid (CSF) levels of amyloid-\u03b2 (A\u03b2) peptides and \u03b1-synuclein (\u03b1-syn) for AD and PD, respectively. However, these diagnostic techniques are not only highly invasive and costly, but they also face limitations in diagnostic accuracy, particularly for preclinical or early stages of diseases. Thus, alternative biomarkers have been sought, preferably those in more accessible and convenient biofluids. Given that antimicrobial peptides and proteins (AMPs) may interact with the neuropathogenesis of AD and PD, AMPs have been recognized as promising candidate biomarkers for AD and PD. Therefore, this review examines the literature on how levels of certain AMPs (lactoferrin, hepcidin, defensin, dermcidin, histatin, cathelicidin L-37, prion protein, amylin or islet amyloid polypeptide, substance P or neurokinin-1, and neuropeptide Y) change in the CSF and more accessible biofluids (serum, plasma, tear, or saliva) in AD and PD patients compared to controls. Based on these findings, this review highlights the advantages, challenges, and future directions of AMP-based biomarkers for AD and\u00a0PD.<\/jats:p>","DOI":"10.1515\/revneuro-2025-0034","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T18:40:36Z","timestamp":1749840036000},"page":"849-879","source":"Crossref","is-referenced-by-count":3,"title":["Antimicrobial peptides and proteins in Alzheimer\u2019s and Parkinson\u2019s diseases: implications for biomarker exploration"],"prefix":"10.1515","volume":"36","author":[{"given":"Shin Jie","family":"Yong","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences , Sunway University , Bandar Sunway , 47500 , Selangor , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Lin","family":"Teoh","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine , Universiti Kebangsaan Malaysia , Cheras, 56000 , Kuala Lumpur , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwar S.","family":"Parhar","sequence":"additional","affiliation":[{"name":"Center Initiative for Training International Researchers , University of Toyama , Gofuku , Toyama , 930-8555 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Soga","sequence":"additional","affiliation":[{"name":"Jeffrey Cheah School of Medicine and Health Sciences , Monash University Malaysia , Bandar Sunway , 47500 , Selangor , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-9849","authenticated-orcid":false,"given":"Wei Ling","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences , Sunway University , Bandar Sunway , 47500 , Selangor , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jactty","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences , Sunway University , Bandar Sunway , 47500 , Selangor , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"2025121816130083970_j_revneuro-2025-0034_ref_001","doi-asserted-by":"crossref","unstructured":"Abbayya, K., Puthanakar, N.Y., Naduwinmani, S., and Chidambar, Y.S. (2015). Association between periodontitis and Alzheimer\u2019s disease. N.\u00a0Am. J.\u00a0Med. Sci. 7: 241\u2013246, https:\/\/doi.org\/10.4103\/1947-2714.159325.","DOI":"10.4103\/1947-2714.159325"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Abner, E.L., Elahi, F.M., Jicha, G.A., Mustapic, M., Al-Janabi, O., Kramer, J.H., Kapogiannis, D., and Goetzl, E.J. (2020). Endothelial-derived plasma exosome proteins in Alzheimer\u2019s disease angiopathy. FASEB J. 34: 5967\u20135974, https:\/\/doi.org\/10.1096\/fj.202000034r.","DOI":"10.1096\/fj.202000034R"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Abu Rumeileh, S., Lattanzio, F., Stanzani Maserati, M., Rizzi, R., Capellari, S., and Parchi, P. (2017). Diagnostic accuracy of a combined analysis of cerebrospinal fluid t-PrP, t-tau, p-tau, and Abeta42 in the differential diagnosis of Creutzfeldt-Jakob disease from Alzheimer\u2019s disease with emphasis on atypical disease variants. J.\u00a0Alzheimers Dis. 55: 1471\u20131480, https:\/\/doi.org\/10.3233\/jad-160740.","DOI":"10.3233\/JAD-160740"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_004","doi-asserted-by":"crossref","unstructured":"Adler, B.L., Yarchoan, M., Hwang, H.M., Louneva, N., Blair, J.A., Palm, R., Smith, M.A., Lee, H.G., Arnold, S.E., and Casadesus, G. (2014). Neuroprotective effects of the amylin analogue pramlintide on Alzheimer\u2019s disease pathogenesis and cognition. Neurobiol. Aging 35: 793\u2013801, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.10.076.","DOI":"10.1016\/j.neurobiolaging.2013.10.076"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., et al.. (2011). The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7: 270\u2013279, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_006","doi-asserted-by":"crossref","unstructured":"Aliu, O. and Chung, K.C. (2012). Assessing strength of evidence in diagnostic tests. Plast. Reconstr. Surg. 129: 989e\u2013998e, https:\/\/doi.org\/10.1097\/prs.0b013e31824ecd61.","DOI":"10.1097\/PRS.0b013e31824ecd61"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Alom, J., Galard, R., Catalan, R., Castellanos, J.M., Schwartz, S., and Tolosa, E. (1990). Cerebrospinal fluid neuropeptide Y in Alzheimer\u2019s disease. Eur. Neurol. 30: 207\u2013210, https:\/\/doi.org\/10.1159\/000117347.","DOI":"10.1159\/000117347"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_008","doi-asserted-by":"crossref","unstructured":"Alperovitch, A., Zerr, I., Pocchiari, M., Mitrova, E., de Pedro Cuesta, J., Hegyi, I., Collins, S., Kretzschmar, H., van Duijn, C., and Will, R.G. (1999). Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 353: 1673\u20131674, https:\/\/doi.org\/10.1016\/s0140-6736(99)01342-2.","DOI":"10.1016\/S0140-6736(99)01342-2"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2021). 2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 17: 327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_010","doi-asserted-by":"crossref","unstructured":"An, L., Sato, H., Konishi, Y., Walker, D.G., Beach, T.G., Rogers, J., and Tooyama, I. (2009). Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer\u2019s disease. Neurosci. Lett. 452: 277\u2013280, https:\/\/doi.org\/10.1016\/j.neulet.2009.01.071.","DOI":"10.1016\/j.neulet.2009.01.071"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_011","doi-asserted-by":"crossref","unstructured":"Antequera, D., Carrero, L., Gonzalez-Sanchez, M., Cantero, J.L., Orive, G., Municio, C., and Carro, E. (2023). Reduced salivary lactoferrin levels in early-onset Alzheimer\u2019s disease. Aging Dis. 15: 945\u2013947, https:\/\/doi.org\/10.14336\/AD.2023.0819.","DOI":"10.14336\/AD.2023.0819"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_012","doi-asserted-by":"crossref","unstructured":"Ashraf, G.M., Tarasov, V.V., Makhmutovsmall, C.A., Chubarev, V.N., Avila-Rodriguez, M., Bachurin, S.O., and Aliev, G. (2019). The possibility of an infectious etiology of Alzheimer disease. Mol. Neurobiol. 56: 4479\u20134491, https:\/\/doi.org\/10.1007\/s12035-018-1388-y.","DOI":"10.1007\/s12035-018-1388-y"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_013","doi-asserted-by":"crossref","unstructured":"Atack, J.R., Beal, M.F., May, C., Kaye, J.A., Mazurek, M.F., Kay, A.D., and Rapoport, S.I. (1988). Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs. Arch. Neurol. 45: 269\u2013274, https:\/\/doi.org\/10.1001\/archneur.1988.00520270043019.","DOI":"10.1001\/archneur.1988.00520270043019"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_014","doi-asserted-by":"crossref","unstructured":"Badinloo, M., Nguyen, E., Suh, W., Alzahrani, F., Castellanos, J., Klichko, V.I., Orr, W.C., and Radyuk, S.N. (2018). Overexpression of antimicrobial peptides contributes to aging through cytotoxic effects in Drosophila tissues. Arch. Insect Biochem. Physiol. 98: e21464, https:\/\/doi.org\/10.1002\/arch.21464.","DOI":"10.1002\/arch.21464"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_015","doi-asserted-by":"crossref","unstructured":"Banks, W.A. and Kastin, A.J. (1998). Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19: 883\u2013889, https:\/\/doi.org\/10.1016\/s0196-9781(98)00018-7.","DOI":"10.1016\/S0196-9781(98)00018-7"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_016","doi-asserted-by":"crossref","unstructured":"Banks, W.A., Kastin, A.J., Maness, L.M., Huang, W., and Jaspan, J.B. (1995). Permeability of the blood-brain barrier to amylin. Life Sci. 57: 1993\u20132001, https:\/\/doi.org\/10.1016\/0024-3205(95)02197-q.","DOI":"10.1016\/0024-3205(95)02197-Q"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_017","doi-asserted-by":"crossref","unstructured":"Bartolome, F., Orive, G., and Carro, E. (2021). Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer\u2019s disease. Alzheimers Dement. (Amst) 13: e12173, https:\/\/doi.org\/10.1002\/dad2.12173.","DOI":"10.1002\/dad2.12173"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_018","doi-asserted-by":"crossref","unstructured":"Baveye, S., Elass, E., Mazurier, J., Spik, G., and Legrand, D. (1999). Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 37: 281\u2013286, https:\/\/doi.org\/10.1515\/cclm.1999.049.","DOI":"10.1515\/CCLM.1999.049"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_019","doi-asserted-by":"crossref","unstructured":"Beatman, E.L., Massey, A., Shives, K.D., Burrack, K.S., Chamanian, M., Morrison, T.E., and Beckham, J.D. (2015). Alpha-synuclein expression restricts RNA viral infections in the brain. J.\u00a0Virol. 90: 2767\u20132782, https:\/\/doi.org\/10.1128\/jvi.02949-15.","DOI":"10.1128\/JVI.02949-15"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_020","doi-asserted-by":"crossref","unstructured":"Bourgade, K., Garneau, H., Giroux, G., Le Page, A.Y., Bocti, C., Dupuis, G., Frost, E.H., and Fulop, T.Jr. (2015). beta-Amyloid peptides display protective activity against the human Alzheimer\u2019s disease-associated herpes simplex virus-1. Biogerontology 16: 85\u201398, https:\/\/doi.org\/10.1007\/s10522-014-9538-8.","DOI":"10.1007\/s10522-014-9538-8"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_021","doi-asserted-by":"crossref","unstructured":"Bourgade, K., Le Page, A., Bocti, C., Witkowski, J.M., Dupuis, G., Frost, E.H., and Fulop, T.Jr. (2016). Protective effect of amyloid-beta peptides against herpes simplex virus-1 infection in a neuronal cell culture model. J.\u00a0Alzheimers Dis. 50: 1227\u20131241, https:\/\/doi.org\/10.3233\/jad-150652.","DOI":"10.3233\/JAD-150652"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_022","doi-asserted-by":"crossref","unstructured":"Braak, H. and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82: 239\u2013259, https:\/\/doi.org\/10.1007\/bf00308809.","DOI":"10.1007\/BF00308809"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_023","doi-asserted-by":"crossref","unstructured":"Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24: 197\u2013211, https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_024","doi-asserted-by":"crossref","unstructured":"Bujang, M.A. and Adnan, T.H. (2016). Requirements for minimum sample size for sensitivity and specificity analysis. J.\u00a0Clin. Diagn. Res. 10: YE01\u2013YE06, https:\/\/doi.org\/10.7860\/JCDR\/2016\/18129.8744.","DOI":"10.7860\/JCDR\/2016\/18129.8744"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_025","doi-asserted-by":"crossref","unstructured":"Campolongo, P., Ratano, P., Ciotti, M.T., Florenzano, F., Nori, S.L., Marolda, R., Palmery, M., Rinaldi, A.M., Zona, C., Possenti, R., et al.. (2013). Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of Kv potassium channels. PLoS One 8: e78036, https:\/\/doi.org\/10.1371\/journal.pone.0078036.","DOI":"10.1371\/journal.pone.0078036"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_026","doi-asserted-by":"crossref","unstructured":"Cannizzaro, C., Tel, B.C., Rose, S., Zeng, B.Y., and Jenner, P. (2003). Increased neuropeptide Y mRNA expression in striatum in Parkinson\u2019s disease. Brain Res. Mol. Brain Res. 110: 169\u2013176, https:\/\/doi.org\/10.1016\/s0169-328x(02)00555-7.","DOI":"10.1016\/S0169-328X(02)00555-7"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_027","doi-asserted-by":"crossref","unstructured":"Carro, E., Bartolome, F., Bermejo-Pareja, F., Villarejo-Galende, A., Molina, J.A., Ortiz, P., Calero, M., Rabano, A., Cantero, J.L., and Orive, G. (2017). Early diagnosis of mild cognitive impairment and Alzheimer\u2019s disease based on salivary lactoferrin. Alzheimers Dement. (Amst) 8: 131\u2013138, https:\/\/doi.org\/10.1016\/j.dadm.2017.04.002.","DOI":"10.1016\/j.dadm.2017.04.002"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_028","doi-asserted-by":"crossref","unstructured":"Casadei, V.M., Ferri, C., Calabrese, E., Grimaldi, L.M., Franceschi, M., Veglia, F., Licastro, F., and Mariani, C. (2001). Prion protein gene polymorphism and Alzheimer\u2019s disease: one modulatory trait of cognitive decline? J.\u00a0Neurol. Neurosurg. Psychiatry 71: 279\u2013280, https:\/\/doi.org\/10.1136\/jnnp.71.2.279.","DOI":"10.1136\/jnnp.71.2.279"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_029","doi-asserted-by":"crossref","unstructured":"Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., and Pezzoli, G. (2011). Diabetes and risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Diabetes Care 34: 2614\u20132623, https:\/\/doi.org\/10.2337\/dc11-1584.","DOI":"10.2337\/dc11-1584"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_030","doi-asserted-by":"crossref","unstructured":"Chatterjee, P., Mohammadi, M., Goozee, K., Shah, T.M., Sohrabi, H.R., Dias, C.B., Shen, K., Asih, P.R., Dave, P., Pedrini, S., et al.. (2020). Serum hepcidin levels in cognitively normal older adults with high neocortical amyloid-beta load. J.\u00a0Alzheimers Dis. 76: 291\u2013301, https:\/\/doi.org\/10.3233\/jad-200162.","DOI":"10.3233\/JAD-200162"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_031","doi-asserted-by":"crossref","unstructured":"Chaudhuri, K.R. and Sauerbier, A. (2016). Parkinson disease. Unravelling the nonmotor mysteries of Parkinson disease. Nat. Rev. Neurol. 12: 10\u201311, https:\/\/doi.org\/10.1038\/nrneurol.2015.236.","DOI":"10.1038\/nrneurol.2015.236"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_032","doi-asserted-by":"crossref","unstructured":"Chen, X.Y., Du, Y.F., and Chen, L. (2018). Neuropeptides exert neuroprotective effects in Alzheimer\u2019s disease. Front. Mol. Neurosci. 11: 493, https:\/\/doi.org\/10.3389\/fnmol.2018.00493.","DOI":"10.3389\/fnmol.2018.00493"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_033","doi-asserted-by":"crossref","unstructured":"Chen, C.K., Wu, Y.T., and Chang, Y.C. (2017). Association between chronic periodontitis and the risk of Alzheimer\u2019s disease: a retrospective, population-based, matched-cohort study. Alzheimers Res. Ther. 9: 56, https:\/\/doi.org\/10.1186\/s13195-017-0282-6.","DOI":"10.1186\/s13195-017-0282-6"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_034","doi-asserted-by":"crossref","unstructured":"Choi, S., Kim, K., Chang, J., Kim, S.M., Kim, S.J., Cho, H.J., and Park, S.M. (2019). Association of chronic periodontitis on Alzheimer\u2019s disease or vascular dementia. J.\u00a0Am. Geriatr. Soc. 67: 1234\u20131239, https:\/\/doi.org\/10.1111\/jgs.15828.","DOI":"10.1111\/jgs.15828"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_035","doi-asserted-by":"crossref","unstructured":"Contini, C., Fadda, L., Lai, G., Masala, C., Olianas, A., Castagnola, M., Messana, I., Iavarone, F., Bizzarro, A., Masullo, C., et al.. (2023). A top-down proteomic approach reveals a salivary protein profile able to classify Parkinson\u2019s disease with respect to Alzheimer\u2019s disease patients and to healthy controls. Proteomics: e2300202, https:\/\/doi.org\/10.1002\/pmic.202300202.","DOI":"10.1002\/pmic.202300202"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_036","doi-asserted-by":"crossref","unstructured":"Contini, C., Olianas, A., Serrao, S., Deriu, C., Iavarone, F., Boroumand, M., Bizzarro, A., Lauria, A., Faa, G., Castagnola, M., et al.. (2021). Top-down proteomics of human saliva highlights anti-inflammatory, antioxidant, and antimicrobial defense responses in alzheimer disease. Front. Neurosci. 15: 668852, https:\/\/doi.org\/10.3389\/fnins.2021.668852.","DOI":"10.3389\/fnins.2021.668852"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_037","doi-asserted-by":"crossref","unstructured":"Contini, C., Serrao, S., Manconi, B., Olianas, A., Iavarone, F., Bizzarro, A., Masullo, C., Castagnola, M., Messana, I., Diaz, G., et al.. (2022). Salivary proteomics reveals significant changes in relation to Alzheimer\u2019s disease and aging. J.\u00a0Alzheimers Dis. 89: 605\u2013622, https:\/\/doi.org\/10.3233\/jad-220246.","DOI":"10.3233\/JAD-220246"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_038","doi-asserted-by":"crossref","unstructured":"Cramer, H., Jost, S., Reuner, C., Milios, E., Geiger, J., and Mundinger, F. (1991). Ventricular fluid neuropeptides in Parkinson\u2019s disease. II. Levels of substance P-like immunoreactivity. Neuropeptides 18: 69\u201373, https:\/\/doi.org\/10.1016\/0143-4179(91)90002-z.","DOI":"10.1016\/0143-4179(91)90002-Z"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_039","doi-asserted-by":"crossref","unstructured":"Cramer, H., Rissler, K., Rosler, N., Strubel, D., Schaudt, D., and Kuntzmann, F. (1989). Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. Eur. Neurol. 29: 1\u20135, https:\/\/doi.org\/10.1159\/000116366.","DOI":"10.1159\/000116366"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_040","doi-asserted-by":"crossref","unstructured":"Cramer, H., Schaudt, D., Rissler, K., Strubel, D., Warter, J.M., and Kuntzmann, F. (1985). Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. J.\u00a0Neurol. 232: 346\u2013351, https:\/\/doi.org\/10.1007\/bf00313833.","DOI":"10.1007\/BF00313833"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_041","doi-asserted-by":"crossref","unstructured":"Crichton, R.R., Dexter, D.T., and Ward, R.J. (2011). Brain iron metabolism and its perturbation in neurological diseases. J.\u00a0Neural Transm. (Vienna) 118: 301\u2013314, https:\/\/doi.org\/10.1007\/s00702-010-0470-z.","DOI":"10.1007\/s00702-010-0470-z"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_042","doi-asserted-by":"crossref","unstructured":"Crystal, H.A. and Davies, P. (1982). Cortical substance P-like immunoreactivity in cases of Alzheimer\u2019s disease and senile dementia of the Alzheimer type. J.\u00a0Neurochem. 38: 1781\u20131784, https:\/\/doi.org\/10.1111\/j.1471-4159.1982.tb06665.x.","DOI":"10.1111\/j.1471-4159.1982.tb06665.x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_043","doi-asserted-by":"crossref","unstructured":"Csosz, E., Emri, G., Kallo, G., Tsaprailis, G., and Tozser, J. (2015). Highly abundant defense proteins in human sweat as revealed by targeted proteomics and label-free quantification mass spectrometry. J.\u00a0Eur. Acad. Dermatol. Venereol. 29: 2024\u20132031, https:\/\/doi.org\/10.1111\/jdv.13221.","DOI":"10.1111\/jdv.13221"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_044","doi-asserted-by":"crossref","unstructured":"Cunningham, T.J., Greenstein, J.I., Loewenstern, J., Degermentzidis, E., and Yao, L. (2015). Anti-inflammatory peptide regulates the supply of heat shock protein 70 monomers: implications for aging and age-related disease. Rejuvenation Res. 18: 136\u2013144, https:\/\/doi.org\/10.1089\/rej.2014.1620.","DOI":"10.1089\/rej.2014.1620"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_045","doi-asserted-by":"crossref","unstructured":"Davies, C.A., Morroll, D.R., Prinja, D., Mann, D.M., and Gibbs, A. (1990). A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer\u2019s disease. J.\u00a0Neurol. Sci. 96: 59\u201373, https:\/\/doi.org\/10.1016\/0022-510x(90)90057-t.","DOI":"10.1016\/0022-510X(90)90057-T"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_046","doi-asserted-by":"crossref","unstructured":"De Lorenzi, E., Chiari, M., Colombo, R., Cretich, M., Sola, L., Vanna, R., Gagni, P., Bisceglia, F., Morasso, C., Lin, J.S., et al.. (2017). Evidence that the human innate immune peptide LL-37 may be a binding partner of amyloid-beta and inhibitor of fibril assembly. J.\u00a0Alzheimers Dis. 59: 1213\u20131226, https:\/\/doi.org\/10.3233\/jad-170223.","DOI":"10.3233\/JAD-170223"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_047","doi-asserted-by":"crossref","unstructured":"Decressac, M., Pain, S., Chabeauti, P.Y., Frangeul, L., Thiriet, N., Herzog, H., Vergote, J., Chalon, S., Jaber, M., and Gaillard, A. (2012). Neuroprotection by neuropeptide Y in cell and animal models of Parkinson\u2019s disease. Neurobiol. Aging 33: 2125\u20132137, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.06.018.","DOI":"10.1016\/j.neurobiolaging.2011.06.018"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_048","doi-asserted-by":"crossref","unstructured":"Del Bo, R., Scarlato, M., Ghezzi, S., Martinelli-Boneschi, F., Fenoglio, C., Galimberti, G., Galbiati, S., Virgilio, R., Galimberti, D., Ferrarese, C., et al.. (2006). Is M129V of PRNP gene associated with Alzheimer\u2019s disease? A case-control study and a meta-analysis. Neurobiol. Aging 27: 770.e771\u2013770.e775, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.05.025.","DOI":"10.1016\/j.neurobiolaging.2005.05.025"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_049","doi-asserted-by":"crossref","unstructured":"Delaby, C., Alcolea, D., Busto, G., Gabelle, A., Ayrignac, X., Bennys, K., Muino, E., Villatoro, P., Fernandez-Cadenas, I., Pradeilles, N., et al.. (2025). Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia. Alzheimers Res. Ther. 17: 42, https:\/\/doi.org\/10.1186\/s13195-025-01696-9.","DOI":"10.1186\/s13195-025-01696-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_050","doi-asserted-by":"crossref","unstructured":"Dharmaraj, G.L., Arigo, F.D., Young, K.A., Martins, R., Mancera, R.L., and Bharadwaj, P. (2022). Novel amylin analogues reduce amyloid-beta cross-seeding aggregation and neurotoxicity. J.\u00a0Alzheimers Dis. 87: 373\u2013390, https:\/\/doi.org\/10.3233\/jad-215339.","DOI":"10.3233\/JAD-215339"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_051","doi-asserted-by":"crossref","unstructured":"Diamond, G., Beckloff, N., Weinberg, A., and Kisich, K.O. (2009). The roles of antimicrobial peptides in innate host defense. Curr. Pharm. Des. 15: 2377\u20132392, https:\/\/doi.org\/10.2174\/138161209788682325.","DOI":"10.2174\/138161209788682325"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_052","doi-asserted-by":"crossref","unstructured":"Dobson, C.B., Sales, S.D., Hoggard, P., Wozniak, M.A., and Crutcher, K.A. (2006). The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J.\u00a0Infect. Dis. 193: 442\u2013450, https:\/\/doi.org\/10.1086\/499280.","DOI":"10.1086\/499280"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_053","doi-asserted-by":"crossref","unstructured":"Dorey, A., Tholance, Y., Vighetto, A., Perret-Liaudet, A., Lachman, I., Krolak-Salmon, P., Wagner, U., Struyfs, H., De Deyn, P.P., El-Moualij, B., et al.. (2015). Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol. 72: 267\u2013275, https:\/\/doi.org\/10.1001\/jamaneurol.2014.4068.","DOI":"10.1001\/jamaneurol.2014.4068"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_054","doi-asserted-by":"crossref","unstructured":"Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A., et al.. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384\u2013386, https:\/\/doi.org\/10.1212\/01.wnl.0000247740.47667.03.","DOI":"10.1212\/01.wnl.0000247740.47667.03"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_055","doi-asserted-by":"crossref","unstructured":"Du, F., Qian, Z.M., Luo, Q., Yung, W.H., and Ke, Y. (2015). Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in iron-overloaded rats. Mol. Neurobiol. 52: 101\u2013114, https:\/\/doi.org\/10.1007\/s12035-014-8847-x.","DOI":"10.1007\/s12035-014-8847-x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_056","doi-asserted-by":"crossref","unstructured":"Duron, E., Vidal, J.S., Grousselle, D., Gabelle, A., Lehmann, S., Pasquier, F., Bombois, S., Buee, L., Allinquant, B., Schraen-Maschke, S., et al.. (2018). Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with amyloid peptides abeta1-42 and tau proteins in elderly patients with mild cognitive impairment. Front. Aging Neurosci. 10: 297, https:\/\/doi.org\/10.3389\/fnagi.2018.00297.","DOI":"10.3389\/fnagi.2018.00297"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_057","doi-asserted-by":"crossref","unstructured":"Edvinsson, L., Minthon, L., Ekman, R., and Gustafson, L. (1993). Neuropeptides in cerebrospinal fluid of patients with Alzheimer\u2019s disease and dementia with frontotemporal lobe degeneration. Dementia 4: 167\u2013171, https:\/\/doi.org\/10.1159\/000107318.","DOI":"10.1159\/000107318"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_058","doi-asserted-by":"crossref","unstructured":"Ehrenberg, A.J., Khatun, A., Coomans, E., Betts, M.J., Capraro, F., Thijssen, E.H., Senkevich, K., Bharucha, T., Jafarpour, M., Young, P.N.E., et al.. (2020). Relevance of biomarkers across different neurodegenerative. Alzheimers Res. Ther. 12: 56, https:\/\/doi.org\/10.1186\/s13195-020-00601-w.","DOI":"10.1186\/s13195-020-00637-y"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_059","doi-asserted-by":"crossref","unstructured":"Eimer, W.A., Vijaya Kumar, D.K., Navalpur Shanmugam, N.K., Rodriguez, A.S., Mitchell, T., Washicosky, K.J., Gyorgy, B., Breakefield, X.O., Tanzi, R.E., and Moir, R.D. (2018). Alzheimer\u2019s disease-associated beta-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 99: 56\u201363.e53, https:\/\/doi.org\/10.1016\/j.neuron.2018.06.030.","DOI":"10.1016\/j.neuron.2018.06.030"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_060","doi-asserted-by":"crossref","unstructured":"El Karim, I.A., Linden, G.J., Orr, D.F., and Lundy, F.T. (2008). Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J.\u00a0Neuroimmunol. 200: 11\u201316, https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.014.","DOI":"10.1016\/j.jneuroim.2008.05.014"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_061","doi-asserted-by":"crossref","unstructured":"Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D.M., and Said Sadier, N. (2018). Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed. J. 41: 63\u201387, https:\/\/doi.org\/10.1016\/j.bj.2018.03.004.","DOI":"10.1016\/j.bj.2018.03.004"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_062","doi-asserted-by":"crossref","unstructured":"Faucheux, B.A., Nillesse, N., Damier, P., Spik, G., Mouatt-Prigent, A., Pierce, A., Leveugle, B., Kubis, N., Hauw, J.J., Agid, Y., et al.. (1995). Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 92: 9603\u20139607, https:\/\/doi.org\/10.1073\/pnas.92.21.9603.","DOI":"10.1073\/pnas.92.21.9603"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_063","doi-asserted-by":"crossref","unstructured":"Fawver, J.N., Ghiwot, Y., Koola, C., Carrera, W., Rodriguez-Rivera, J., Hernandez, C., Dineley, K.T., Kong, Y., Li, J., Jhamandas, J., et al.. (2014). Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer\u2019s disease. Curr. Alzheimer Res. 11: 928\u2013940, https:\/\/doi.org\/10.2174\/1567205011666141107124538.","DOI":"10.2174\/1567205011666141107124538"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_064","doi-asserted-by":"crossref","unstructured":"Fernandez, A., de Ceballos, M.L., Jenner, P., and Marsden, C.D. (1992). Striatal neuropeptide levels in Parkinson\u2019s disease patients. Neurosci. Lett. 145: 171\u2013174, https:\/\/doi.org\/10.1016\/0304-3940(92)90014-x.","DOI":"10.1016\/0304-3940(92)90014-X"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_065","doi-asserted-by":"crossref","unstructured":"Fillebeen, C., Dehouck, B., Benaissa, M., Dhennin-Duthille, I., Cecchelli, R., and Pierce, A. (1999a). Tumor necrosis factor-alpha increases lactoferrin transcytosis through the blood-brain barrier. J.\u00a0Neurochem. 73: 2491\u20132500, https:\/\/doi.org\/10.1046\/j.1471-4159.1999.0732491.x.","DOI":"10.1046\/j.1471-4159.1999.0732491.x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_066","doi-asserted-by":"crossref","unstructured":"Fillebeen, C., Descamps, L., Dehouck, M.P., Fenart, L., Benaissa, M., Spik, G., Cecchelli, R., and Pierce, A. (1999b). Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J.\u00a0Biol. Chem. 274: 7011\u20137017, https:\/\/doi.org\/10.1074\/jbc.274.11.7011.","DOI":"10.1074\/jbc.274.11.7011"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_067","doi-asserted-by":"crossref","unstructured":"Fillebeen, C., Mitchell, V., Dexter, D., Benaissa, M., Beauvillain, J., Spik, G., and Pierce, A. (1999c). Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Brain Res. Mol. Brain Res. 72: 183\u2013194, https:\/\/doi.org\/10.1016\/s0169-328x(99)00221-1.","DOI":"10.1016\/S0169-328X(99)00221-1"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_068","doi-asserted-by":"crossref","unstructured":"Fillebeen, C., Ruchoux, M.M., Mitchell, V., Vincent, S., Benaissa, M., and Pierce, A. (2001). Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res. Mol. Brain Res. 96: 103\u2013113, https:\/\/doi.org\/10.1016\/s0169-328x(01)00216-9.","DOI":"10.1016\/S0169-328X(01)00216-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_069","doi-asserted-by":"crossref","unstructured":"Fleszar, M.G., Wisniewski, J., Berdowska, I., Zielinski, B., Zboch, M., Diakowska, D., Gamian, A., and Krzystek-Korpacka, M. (2019). Systemic hepcidin quantified with LC-MS\/MS in dementia in association with disease pathology and severity and with structural changes in the brain. Peptides 122: 170169, https:\/\/doi.org\/10.1016\/j.peptides.2019.170169.","DOI":"10.1016\/j.peptides.2019.170169"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_070","doi-asserted-by":"crossref","unstructured":"Fruitwala, S., El-Naccache, D.W., and Chang, T.L. (2019). Multifaceted immune functions of human defensins and underlying mechanisms. Semin. Cell Dev. Biol. 88: 163\u2013172, https:\/\/doi.org\/10.1016\/j.semcdb.2018.02.023.","DOI":"10.1016\/j.semcdb.2018.02.023"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_071","doi-asserted-by":"crossref","unstructured":"Fuller, K.N.Z., Miranda, E.R., Thyfault, J.P., Morris, J.K., and Haus, J.M. (2018). Metabolic derangements contribute to reduced sRAGE isoforms in subjects with Alzheimer\u2019s disease. Mediat. Inflamm. 2018: 2061376, https:\/\/doi.org\/10.1155\/2018\/2061376.","DOI":"10.1155\/2018\/2061376"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_072","doi-asserted-by":"crossref","unstructured":"Fulop, T., Itzhaki, R.F., Balin, B.J., Miklossy, J., and Barron, A.E. (2018). Role of microbes in the development of Alzheimer\u2019s disease: state of the art\u00a0\u2013\u00a0an international symposium presented at the 2017 IAGG congress in San Francisco. Front. Genet. 9: 362, https:\/\/doi.org\/10.3389\/fgene.2018.00362.","DOI":"10.3389\/fgene.2018.00362"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_073","doi-asserted-by":"crossref","unstructured":"Gaglione, R., Cesaro, A., Dell\u2019Olmo, E., Della Ventura, B., Casillo, A., Di Girolamo, R., Velotta, R., Notomista, E., Veldhuizen, E.J.A., Corsaro, M.M., et al.. (2019). Effects of human antimicrobial cryptides identified in apolipoprotein B depend on specific features of bacterial strains. Sci. Rep. 9: 6728, https:\/\/doi.org\/10.1038\/s41598-019-43063-3.","DOI":"10.1038\/s41598-019-43063-3"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_074","doi-asserted-by":"crossref","unstructured":"Ganz, T. (2003). Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3: 710\u2013720, https:\/\/doi.org\/10.1038\/nri1180.","DOI":"10.1038\/nri1180"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_075","doi-asserted-by":"crossref","unstructured":"Ganz, T., Selsted, M.E., Szklarek, D., Harwig, S.S., Daher, K., Bainton, D.F., and Lehrer, R.I. (1985). Defensins. Natural peptide antibiotics of human neutrophils. J.\u00a0Clin. Invest. 76: 1427\u20131435, https:\/\/doi.org\/10.1172\/jci112120.","DOI":"10.1172\/JCI112120"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_076","doi-asserted-by":"crossref","unstructured":"Garcia-Montoya, I.A., Cendon, T.S., Arevalo-Gallegos, S., and Rascon-Cruz, Q. (2012). Lactoferrin a multiple bioactive protein: an overview. Biochim. Biophys. Acta 1820: 226\u2013236, https:\/\/doi.org\/10.1016\/j.bbagen.2011.06.018.","DOI":"10.1016\/j.bbagen.2011.06.018"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_077","doi-asserted-by":"crossref","unstructured":"Geng, X., Lou, H., Wang, J., Li, L., Swanson, A.L., Sun, M., Beers-Stolz, D., Watkins, S., Perez, R.G., and Drain, P. (2011). alpha-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am. J.\u00a0Physiol. Endocrinol. Metab. 300: E276\u2013E286, https:\/\/doi.org\/10.1152\/ajpendo.00262.2010.","DOI":"10.1152\/ajpendo.00262.2010"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_078","doi-asserted-by":"crossref","unstructured":"Gleerup, H.S., Jensen, C.S., Hogh, P., Hasselbalch, S.G., and Simonsen, A.H. (2021). Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer\u2019s disease in a mixed memory clinic population. EBioMedicine 67: 103361, https:\/\/doi.org\/10.1016\/j.ebiom.2021.103361.","DOI":"10.1016\/j.ebiom.2021.103361"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_079","doi-asserted-by":"crossref","unstructured":"Gonzalez-Sanchez, M., Bartolome, F., Antequera, D., Puertas-Martin, V., Gonzalez, P., Gomez-Grande, A., Llamas-Velasco, S., Herrero-San Martin, A., Perez-Martinez, D., Villarejo-Galende, A., et al.. (2020). Decreased salivary lactoferrin levels are specific to Alzheimer\u2019s disease. EBioMedicine 57: 102834, https:\/\/doi.org\/10.1016\/j.ebiom.2020.102834.","DOI":"10.1016\/j.ebiom.2020.102834"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_080","doi-asserted-by":"crossref","unstructured":"Grau, A.J., Willig, V., Fogel, W., and Werle, E. (2001). Assessment of plasma lactoferrin in Parkinson\u2019s disease. Mov. Disord. 16: 131\u2013134, https:\/\/doi.org\/10.1002\/1531-8257(200101)16:1<131::aid-mds1008>3.0.co;2-o.","DOI":"10.1002\/1531-8257(200101)16:1<131::AID-MDS1008>3.0.CO;2-O"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_081","doi-asserted-by":"crossref","unstructured":"Gudmundsson, G.H., Agerberth, B., Odeberg, J., Bergman, T., Olsson, B., and Salcedo, R. (1996). The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J.\u00a0Biochem. 238: 325\u2013332, https:\/\/doi.org\/10.1111\/j.1432-1033.1996.0325z.x.","DOI":"10.1111\/j.1432-1033.1996.0325z.x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_082","doi-asserted-by":"crossref","unstructured":"Guo, C., Yang, Z.H., Zhang, S., Chai, R., Xue, H., Zhang, Y.H., Li, J.Y., and Wang, Z.Y. (2017). Intranasal lactoferrin enhances alpha-secretase-dependent amyloid precursor protein processing via the ERK1\/2-CREB and HIF-1alpha pathways in an Alzheimer\u2019s disease mouse model. Neuropsychopharmacology 42: 2504\u20132515, https:\/\/doi.org\/10.1038\/npp.2017.8.","DOI":"10.1038\/npp.2017.8"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_083","doi-asserted-by":"crossref","unstructured":"Guzman-Martinez, L., Maccioni, R.B., Andrade, V., Navarrete, L.P., Pastor, M.G., and Ramos-Escobar, N. (2019). Neuroinflammation as a common feature of neurodegenerative disorders. Front. Pharmacol 10: 1008, https:\/\/doi.org\/10.3389\/fphar.2019.01008.","DOI":"10.3389\/fphar.2019.01008"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_084","doi-asserted-by":"crossref","unstructured":"Hamm-Alvarez, S.F., Janga, S.R., Edman, M.C., Feigenbaum, D., Freire, D., Mack, W.J., Okamoto, C.T., and Lew, M.F. (2019a). Levels of oligomeric alpha-synuclein in reflex tears distinguish Parkinson\u2019s disease patients from healthy controls. Biomark. Med. 13: 1447\u20131457, https:\/\/doi.org\/10.2217\/bmm-2019-0315.","DOI":"10.2217\/bmm-2019-0315"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_085","doi-asserted-by":"crossref","unstructured":"Hamm-Alvarez, S.F., Okamoto, C.T., Janga, S.R., Feigenbaum, D., Edman, M.C., Freire, D., Shah, M., Ghanshani, R., Mack, W.J., and Lew, M.F. (2019b). Oligomeric alpha-synuclein is increased in basal tears of Parkinson\u2019s patients. Biomark. Med. 13: 941\u2013952, https:\/\/doi.org\/10.2217\/bmm-2019-0167.","DOI":"10.2217\/bmm-2019-0167"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_086","doi-asserted-by":"crossref","unstructured":"Hansen, C.J., Burnell, K.K., and Brogden, K.A. (2006). Antimicrobial activity of substance P and neuropeptide Y against laboratory strains of bacteria and oral microorganisms. J.\u00a0Neuroimmunol. 177: 215\u2013218, https:\/\/doi.org\/10.1016\/j.jneuroim.2006.05.011.","DOI":"10.1016\/j.jneuroim.2006.05.011"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_087","doi-asserted-by":"crossref","unstructured":"Hartmann, S. and Ledur Kist, T.B. (2018). A review of biomarkers of Alzheimer\u2019s disease in noninvasive samples. Biomark. Med. 12: 677\u2013690, https:\/\/doi.org\/10.2217\/bmm-2017-0388.","DOI":"10.2217\/bmm-2017-0388"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_088","doi-asserted-by":"crossref","unstructured":"Hasenohrl, R.U., Frisch, C., Nikolaus, S., and Huston, J.P. (1994). Chronic administration of neurokinin SP improves maze performance in aged Rattus norvegicus. Behav. Neural Biol. 62: 110\u2013120, https:\/\/doi.org\/10.1016\/s0163-1047(05)80032-9.","DOI":"10.1016\/S0163-1047(05)80032-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_089","doi-asserted-by":"crossref","unstructured":"Hazrati, E., Galen, B., Lu, W., Wang, W., Ouyang, Y., Keller, M.J., Lehrer, R.I., and Herold, B.C. (2006). Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J.\u00a0Immunol. 177: 8658\u20138666, https:\/\/doi.org\/10.4049\/jimmunol.177.12.8658.","DOI":"10.4049\/jimmunol.177.12.8658"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_090","doi-asserted-by":"crossref","unstructured":"Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., and Evans, D.A. (2003). Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60: 1119\u20131122, https:\/\/doi.org\/10.1001\/archneur.60.8.1119.","DOI":"10.1001\/archneur.60.8.1119"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_091","doi-asserted-by":"crossref","unstructured":"Heilig, M., Sjogren, M., Blennow, K., Ekman, R., and Wallin, A. (1995). Cerebrospinal fluid neuropeptides in Alzheimer\u2019s disease and vascular dementia. Biol. Psychiatry 38: 210\u2013216, https:\/\/doi.org\/10.1016\/0006-3223(94)00239-y.","DOI":"10.1016\/0006-3223(94)00239-Y"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_092","doi-asserted-by":"crossref","unstructured":"Hooper, N.M. and Turner, A.J. (2008). A new take on prions: preventing Alzheimer\u2019s disease. Trends Biochem. Sci. 33: 151\u2013155, https:\/\/doi.org\/10.1016\/j.tibs.2008.01.004.","DOI":"10.1016\/j.tibs.2008.01.004"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_093","doi-asserted-by":"crossref","unstructured":"Horvath, I. and Wittung-Stafshede, P. (2016). Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease. Proc. Natl. Acad. Sci. U. S. A. 113: 12473\u201312477, https:\/\/doi.org\/10.1073\/pnas.1610371113.","DOI":"10.1073\/pnas.1610371113"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_094","doi-asserted-by":"crossref","unstructured":"Hrubesova, K., Fouskova, M., Habartova, L., Fisar, Z., Jirak, R., Raboch, J., and Setnicka, V. (2019). Search for biomarkers of Alzheimer\u2019s disease: recent insights, current challenges and future prospects. Clin. Biochem. 72: 39\u201351, https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.04.002.","DOI":"10.1016\/j.clinbiochem.2019.04.002"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_095","doi-asserted-by":"crossref","unstructured":"Hu, Y., Yu, S.Y., Zuo, L.J., Piao, Y.S., Cao, C.J., Wang, F., Chen, Z.J., Du, Y., Lian, T.H., Liu, G.F., et al.. (2015). Investigation on abnormal iron metabolism and related inflammation in Parkinson disease patients with probable RBD. PLoS One 10: e0138997, https:\/\/doi.org\/10.1371\/journal.pone.0138997.","DOI":"10.1371\/journal.pone.0138997"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_096","doi-asserted-by":"crossref","unstructured":"Huang, X., Atwood, C.S., Moir, R.D., Hartshorn, M.A., Vonsattel, J.P., Tanzi, R.E., and Bush, A.I. (1997). Zinc-induced Alzheimer\u2019s Abeta1\u201340 aggregation is mediated by conformational factors. J.\u00a0Biol. Chem. 272: 26464\u201326470, https:\/\/doi.org\/10.1074\/jbc.272.42.26464.","DOI":"10.1074\/jbc.272.42.26464"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_097","doi-asserted-by":"crossref","unstructured":"Hughes, A.J., Daniel, S.E., Kilford, L., and Lees, A.J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J.\u00a0Neurol. Neurosurg. Psychiatry 55: 181\u2013184, https:\/\/doi.org\/10.1136\/jnnp.55.3.181.","DOI":"10.1136\/jnnp.55.3.181"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_098","doi-asserted-by":"crossref","unstructured":"Jack, C.R.Jr., Albert, M.S., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., Thies, B., and Phelps, C.H. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7: 257\u2013262, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.004.","DOI":"10.1016\/j.jalz.2011.03.004"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_099","doi-asserted-by":"crossref","unstructured":"Jack, C.R.Jr., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., et al.. (2018). NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14: 535\u2013562, https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_100","doi-asserted-by":"crossref","unstructured":"Jackson, K., Barisone, G.A., Diaz, E., Jin, L.W., DeCarli, C., and Despa, F. (2013). Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann. Neurol. 74: 517\u2013526, https:\/\/doi.org\/10.1002\/ana.23956.","DOI":"10.1002\/ana.23956"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_101","doi-asserted-by":"crossref","unstructured":"Johansson, P., Almqvist, E.G., Wallin, A., Johansson, J.O., Andreasson, U., Blennow, K., Zetterberg, H., and Svensson, J. (2015). Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer\u2019s disease. Neurosci. Lett. 609: 58\u201362, https:\/\/doi.org\/10.1016\/j.neulet.2015.10.006.","DOI":"10.1016\/j.neulet.2015.10.006"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_102","doi-asserted-by":"crossref","unstructured":"Johnson, M.B., Young, A.D., and Marriott, I. (2016). The therapeutic potential of targeting substance P\/NK-1R interactions in inflammatory CNS disorders. Front. Cell. Neurosci. 10: 296, https:\/\/doi.org\/10.3389\/fncel.2016.00296.","DOI":"10.3389\/fncel.2016.00296"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_103","doi-asserted-by":"crossref","unstructured":"Kallo, G., Emri, M., Varga, Z., Ujhelyi, B., Tozser, J., Csutak, A., and Csosz, E. (2016). Changes in the chemical barrier composition of tears in Alzheimer\u2019s disease reveal potential tear diagnostic biomarkers. PLoS One 11: e0158000, https:\/\/doi.org\/10.1371\/journal.pone.0158000.","DOI":"10.1371\/journal.pone.0158000"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_104","doi-asserted-by":"crossref","unstructured":"Kang, S., Jeong, H., Baek, J.H., Lee, S.J., Han, S.H., Cho, H.J., Kim, H., Hong, H.S., Kim, Y.H., Yi, E.C., et al.. (2016). PiB-PET imaging-based serum proteome profiles predict mild cognitive impairment and Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 53: 1563\u20131576, https:\/\/doi.org\/10.3233\/jad-160025.","DOI":"10.3233\/JAD-160025"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_105","unstructured":"Kawamata, T., Tooyama, I., Yamada, T., Walker, D.G., and McGeer, P.L. (1993). Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am. J.\u00a0Pathol. 142: 1574\u20131585."},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_106","doi-asserted-by":"crossref","unstructured":"Kaye, E.K., Valencia, A., Baba, N., Spiro, A.3rd, Dietrich, T., and Garcia, R.I. (2010). Tooth loss and periodontal disease predict poor cognitive function in older men. J.\u00a0Am. Geriatr. Soc. 58: 713\u2013718, https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02788.x.","DOI":"10.1111\/j.1532-5415.2010.02788.x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_107","doi-asserted-by":"crossref","unstructured":"Kertes, E., Laszlo, K., Berta, B., and Lenard, L. (2009). Effects of substance P microinjections into the globus pallidus and central nucleus of amygdala on passive avoidance learning in rats. Behav. Brain Res. 198: 397\u2013403, https:\/\/doi.org\/10.1016\/j.bbr.2008.11.021.","DOI":"10.1016\/j.bbr.2008.11.021"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_108","doi-asserted-by":"crossref","unstructured":"Koide, S., Onishi, H., Hashimoto, H., Kai, T., and Yamagami, S. (1995). Plasma neuropeptide Y is reduced in patients with Alzheimer\u2019s disease. Neurosci. Lett. 198: 149\u2013151, https:\/\/doi.org\/10.1016\/0304-3940(95)11973-z.","DOI":"10.1016\/0304-3940(95)11973-Z"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_109","doi-asserted-by":"crossref","unstructured":"Kowall, N.W. and Beal, M.F. (1988). Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer\u2019s disease. Ann. Neurol. 23: 105\u2013114, https:\/\/doi.org\/10.1002\/ana.410230202.","DOI":"10.1002\/ana.410230202"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_110","doi-asserted-by":"crossref","unstructured":"Kowall, N.W., Beal, M.F., Busciglio, J., Duffy, L.K., and Yankner, B.A. (1991). An in\u00a0vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc. Natl. Acad. Sci. U. S. A. 88: 7247\u20137251, https:\/\/doi.org\/10.1073\/pnas.88.16.7247.","DOI":"10.1073\/pnas.88.16.7247"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_111","doi-asserted-by":"crossref","unstructured":"Krbot, K., Hermann, P., Skoric, M.K., Zerr, I., Sepulveda-Falla, D., Goebel, S., Matschke, J., Krasemann, S., and Glatzel, M. (2018). Distinct microglia profile in Creutzfeldt-Jakob disease and Alzheimer\u2019s disease is independent of disease kinetics. Neuropathology 38: 591\u2013600, https:\/\/doi.org\/10.1111\/neup.12517.","DOI":"10.1111\/neup.12517"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_112","doi-asserted-by":"crossref","unstructured":"Kumar, U. (2005). Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer\u2019s disease brain: an immunohistochemical analysis. Neuroscience 134: 525\u2013538, https:\/\/doi.org\/10.1016\/j.neuroscience.2005.04.001.","DOI":"10.1016\/j.neuroscience.2005.04.001"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_113","doi-asserted-by":"crossref","unstructured":"Kumar, D.K., Choi, S.H., Washicosky, K.J., Eimer, W.A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L.E., Tanzi, R.E., et al.. (2016). Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer\u2019s disease. Sci. Transl. Med. 8: 340ra372, https:\/\/doi.org\/10.1126\/scitranslmed.aaf1059.","DOI":"10.1126\/scitranslmed.aaf1059"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_114","doi-asserted-by":"crossref","unstructured":"Kweon, O.J., Youn, Y.C., Lim, Y.K., Lee, M.K., and Kim, H.R. (2019). Clinical utility of serum hepcidin and iron profile measurements in Alzheimer\u2019s disease. J.\u00a0Neurol. Sci. 403: 85\u201391, https:\/\/doi.org\/10.1016\/j.jns.2019.06.008.","DOI":"10.1016\/j.jns.2019.06.008"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_115","doi-asserted-by":"crossref","unstructured":"Kwiatek-Majkusiak, J., Geremek, M., Koziorowski, D., Tomasiuk, R., Szlufik, S., and Friedman, A. (2018). Higher serum levels of pro-hepcidin in patients with Parkinson\u2019s disease treated with deep brain stimulation. Neurosci. Lett. 684: 205\u2013209, https:\/\/doi.org\/10.1016\/j.neulet.2018.06.031.","DOI":"10.1016\/j.neulet.2018.06.031"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_116","doi-asserted-by":"crossref","unstructured":"Kwiatek-Majkusiak, J., Geremek, M., Koziorowski, D., Tomasiuk, R., Szlufik, S., and Friedman, A. (2020). Serum levels of hepcidin and interleukin 6 in Parkinson\u2019s disease. Acta Neurobiol. Exp. (Wars) 80: 297\u2013304, https:\/\/doi.org\/10.21307\/ane-2020-026.","DOI":"10.21307\/ane-2020-026"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_117","doi-asserted-by":"crossref","unstructured":"Last, N.B. and Miranker, A.D. (2013). Common mechanism unites membrane poration by amyloid and antimicrobial peptides. Proc. Natl. Acad. Sci. U. S. A. 110: 6382\u20136387, https:\/\/doi.org\/10.1073\/pnas.1219059110.","DOI":"10.1073\/pnas.1219059110"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_118","doi-asserted-by":"crossref","unstructured":"Lathe, R. and Darlix, J.L. (2017). Prion protein PRNP: a new player in innate immunity? The abeta connection. J.\u00a0Alzheimers Dis. Rep. 1: 263\u2013275, https:\/\/doi.org\/10.3233\/adr-170037.","DOI":"10.3233\/ADR-170037"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_119","doi-asserted-by":"crossref","unstructured":"Lee, J.C., Kim, S.J., Hong, S., and Kim, Y. (2019). Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers. Exp. Mol. Med. 51: 53, https:\/\/doi.org\/10.1038\/s12276-019-0250-2.","DOI":"10.1038\/s12276-019-0250-2"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_120","doi-asserted-by":"crossref","unstructured":"Lee, M., Shi, X., Barron, A.E., McGeer, E., and McGeer, P.L. (2015). Human antimicrobial peptide LL-37 induces glial-mediated neuroinflammation. Biochem. Pharmacol. 94: 130\u2013141, https:\/\/doi.org\/10.1016\/j.bcp.2015.02.003.","DOI":"10.1016\/j.bcp.2015.02.003"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_268","doi-asserted-by":"crossref","unstructured":"Leng, B., Sun, H., Zhao, J., Liu, Y., Shen, T., Liu, W., Liu, X., Tan, M., Li, F., Zhang, J., et al.. (2020). Plasma exosomal prion protein levels are correlated with cognitive decline in PD patients. Neurosci. Lett. 723: 134866, https:\/\/doi.org\/10.1016\/j.neulet.2020.134866.","DOI":"10.1016\/j.neulet.2020.134866"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_121","doi-asserted-by":"crossref","unstructured":"Leveugle, B., Faucheux, B.A., Bouras, C., Nillesse, N., Spik, G., Hirsch, E.C., Agid, Y., and Hof, P.R. (1996). Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson\u2019s disease cases. Acta Neuropathol. 91: 566\u2013572, https:\/\/doi.org\/10.1007\/s004010050468.","DOI":"10.1007\/s004010050468"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_122","doi-asserted-by":"crossref","unstructured":"Leveugle, B., Spik, G., Perl, D.P., Bouras, C., Fillit, H.M., and Hof, P.R. (1994). The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 650: 20\u201331, https:\/\/doi.org\/10.1016\/0006-8993(94)90202-x.","DOI":"10.1016\/0006-8993(94)90202-X"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_123","doi-asserted-by":"crossref","unstructured":"Levy, R., Vila, M., Herrero, M.T., Faucheux, B., Agid, Y., and Hirsch, E.C. (1995). Striatal expression of substance P and methionin-enkephalin in genes in patients with Parkinson\u2019s disease. Neurosci. Lett. 199: 220\u2013224, https:\/\/doi.org\/10.1016\/0304-3940(95)12011-r.","DOI":"10.1016\/0304-3940(95)12011-R"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_124","doi-asserted-by":"crossref","unstructured":"Lezi, E., Zhou, T., Koh, S., Chuang, M., Sharma, R., Pujol, N., Chisholm, A.D., Eroglu, C., Matsunami, H., and Yan, D. (2018). An antimicrobial peptide and its neuronal receptor regulate dendrite degeneration in aging and infection. Neuron 97: 125\u2013138.e125, https:\/\/doi.org\/10.1016\/j.neuron.2017.12.001.","DOI":"10.1016\/j.neuron.2017.12.001"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_125","doi-asserted-by":"crossref","unstructured":"Li, L., Holscher, C., Chen, B.B., Zhang, Z.F., and Liu, Y.Z. (2011). Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus. Biol. Trace Elem. Res. 143: 1581\u20131593, https:\/\/doi.org\/10.1007\/s12011-011-8967-3.","DOI":"10.1007\/s12011-011-8967-3"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_126","doi-asserted-by":"crossref","unstructured":"Li, M., Hu, J., Yuan, X., Shen, L., Zhu, L., and Luo, Q. (2020). Hepcidin decreases rotenone-induced alpha-synuclein accumulation via autophagy in SH-SY5Y cells. Front. Mol. Neurosci. 13: 560891, https:\/\/doi.org\/10.3389\/fnmol.2020.560891.","DOI":"10.3389\/fnmol.2020.560891"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_127","doi-asserted-by":"crossref","unstructured":"Lian, T.H., Guo, P., Zuo, L.J., Hu, Y., Yu, S.Y., Yu, Q.J., Jin, Z., Wang, R.D., Li, L.X., and Zhang, W. (2019). Tremor-dominant in Parkinson disease: the relevance to iron metabolism and inflammation. Front. Neurosci. 13: 255, https:\/\/doi.org\/10.3389\/fnins.2019.00255.","DOI":"10.3389\/fnins.2019.00255"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_128","doi-asserted-by":"crossref","unstructured":"Liang, T., Qian, Z.M., Mu, M.D., Yung, W.H., and Ke, Y. (2020). Brain hepcidin suppresses major pathologies in experimental parkinsonism. iScience 23: 101284, https:\/\/doi.org\/10.1016\/j.isci.2020.101284.","DOI":"10.1016\/j.isci.2020.101284"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_129","doi-asserted-by":"crossref","unstructured":"Licastro, F., Pedrini, S., Davis, L.J., Caputo, L., Tagliabue, J., Savorani, G., Cucinotta, D., and Annoni, G. (2001). Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis. Assoc. Disord. 15: 51\u201355, https:\/\/doi.org\/10.1097\/00002093-200101000-00007.","DOI":"10.1097\/00002093-200101000-00007"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_130","doi-asserted-by":"crossref","unstructured":"Limphaibool, N., Iwanowski, P., Holstad, M.J.V., Kobylarek, D., and Kozubski, W. (2019). Infectious etiologies of parkinsonism: pathomechanisms and clinical implications. Front. Neurol. 10: 652, https:\/\/doi.org\/10.3389\/fneur.2019.00652.","DOI":"10.3389\/fneur.2019.00652"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_131","doi-asserted-by":"crossref","unstructured":"Litvan, I., MacIntyre, A., Goetz, C.G., Wenning, G.K., Jellinger, K., Verny, M., Bartko, J.J., Jankovic, J., McKee, A., Brandel, J.P., et al.. (1998). Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch. Neurol. 55: 969\u2013978, https:\/\/doi.org\/10.1001\/archneur.55.7.969.","DOI":"10.1001\/archneur.55.7.969"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_132","doi-asserted-by":"crossref","unstructured":"Liu, X.M., Shu, S.Y., Zeng, C.C., Cai, Y.F., Zhang, K.H., Wang, C.X., and Fang, J. (2011). The role of substance P in the marginal division of the neostriatum in learning and memory is mediated through the neurokinin 1 receptor in rats. Neurochem. Res. 36: 1896\u20131902, https:\/\/doi.org\/10.1007\/s11064-011-0511-5.","DOI":"10.1007\/s11064-011-0511-5"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_133","doi-asserted-by":"crossref","unstructured":"Liu, Z., Zhu, H., Fang, G.G., Walsh, K., Mwamburi, M., Wolozin, B., Abdul-Hay, S.O., Ikezu, T., Leissring, M.A., and Qiu, W.Q. (2012). Characterization of insulin degrading enzyme and other amyloid-beta degrading proteases in human serum: a role in Alzheimer\u2019s disease? J.\u00a0Alzheimers Dis. 29: 329\u2013340, https:\/\/doi.org\/10.3233\/jad-2011-111472.","DOI":"10.3233\/JAD-2011-111472"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_134","doi-asserted-by":"crossref","unstructured":"Llorens, F., Villar-Pique, A., Schmitz, M., Diaz-Lucena, D., Wohlhage, M., Hermann, P., Goebel, S., Schmidt, I., Glatzel, M., Hauw, J.J., et al.. (2019). Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases. Neuropathol. Appl. Neurobiol. 46: 240\u2013254, https:\/\/doi.org\/10.1111\/nan.12573.","DOI":"10.1111\/nan.12573"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_135","doi-asserted-by":"crossref","unstructured":"Looker, K.J., Magaret, A.S., May, M.T., Turner, K.M., Vickerman, P., Gottlieb, S.L., and Newman, L.M. (2015). Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One 10: e0140765, https:\/\/doi.org\/10.1371\/journal.pone.0140765.","DOI":"10.1371\/journal.pone.0140765"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_136","doi-asserted-by":"crossref","unstructured":"Lu, C.T., Jin, R.R., Jiang, Y.N., Lin, Q., Yu, W.Z., Mao, K.L., Tian, F.R., Zhao, Y.P., and Zhao, Y.Z. (2015). Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in\u00a0vitro and in\u00a0vivo study. Drug Des. Devel. Ther. 9: 1955\u20131962, https:\/\/doi.org\/10.2147\/dddt.s77237.","DOI":"10.2147\/DDDT.S77237"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_137","doi-asserted-by":"crossref","unstructured":"Ly, H., Verma, N., Sharma, S., Kotiya, D., Despa, S., Abner, E.L., Nelson, P.T., Jicha, G.A., Wilcock, D.M., Goldstein, L.B., et al.. (2021). The association of circulating amylin with beta-amyloid in familial Alzheimer\u2019s disease. Alzheimers Dement. (N. Y.) 7: e12130, https:\/\/doi.org\/10.1002\/trc2.12130.","DOI":"10.1002\/trc2.12130"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_138","doi-asserted-by":"crossref","unstructured":"Mahley, R.W., Weisgraber, K.H., and Huang, Y. (2009). Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer\u2019s disease to AIDS. J.\u00a0Lipid Res. 50 Suppl: S183\u2013S188, https:\/\/doi.org\/10.1194\/jlr.r800069-jlr200.","DOI":"10.1194\/jlr.R800069-JLR200"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_139","doi-asserted-by":"crossref","unstructured":"Manolov, V. (2017). The role of iron homeostasis in Alzheimer\u2019s disease. Alzheimers Neurodegener. Dis. 3: 1\u20134, https:\/\/doi.org\/10.24966\/and-9608\/100011.","DOI":"10.24966\/AND-9608\/100011"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_140","doi-asserted-by":"crossref","unstructured":"Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., and Nappi, G. (1992). Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson\u2019s disease, multiple system atrophy and dementia of the Alzheimer type. J.\u00a0Neural. Transm. Park. Dis. Dement. Sect. 4: 191\u2013205, https:\/\/doi.org\/10.1007\/bf02260903.","DOI":"10.1007\/BF02260903"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_141","doi-asserted-by":"crossref","unstructured":"Martin-Bastida, A., Tilley, B.S., Bansal, S., Gentleman, S.M., Dexter, D.T., and Ward, R.J. (2021). Iron and inflammation: in\u00a0vivo and post-mortem studies in Parkinson\u2019s disease. J.\u00a0Neural Transm. (Vienna) 128: 15\u201325, https:\/\/doi.org\/10.1007\/s00702-020-02271-2.","DOI":"10.1007\/s00702-020-02271-2"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_142","doi-asserted-by":"crossref","unstructured":"Martinez, M., Frank, A., and Hernanz, A. (1993). Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. J.\u00a0Neuroimmunol. 48: 235\u2013240, https:\/\/doi.org\/10.1016\/0165-5728(93)90197-7.","DOI":"10.1016\/0165-5728(93)90197-7"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_143","doi-asserted-by":"crossref","unstructured":"Martinez-Valbuena, I., Amat-Villegas, I., Valenti-Azcarate, R., Carmona-Abellan, M.D.M., Marcilla, I., Tunon, M.T., and Luquin, M.R. (2018). Interaction of amyloidogenic proteins in pancreatic beta cells from subjects with synucleinopathies. Acta Neuropathol. 135: 877\u2013886, https:\/\/doi.org\/10.1007\/s00401-018-1832-0.","DOI":"10.1007\/s00401-018-1832-0"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_144","doi-asserted-by":"crossref","unstructured":"Martinez-Valbuena, I., Valenti-Azcarate, R., Amat-Villegas, I., Riverol, M., Marcilla, I., de Andrea, C.E., Sanchez-Arias, J.A., Del Mar Carmona-Abellan, M., Marti, G., Erro, M.E., et al.. (2019). Amylin as a potential link between type 2 diabetes and alzheimer disease. Ann. Neurol. 86: 539\u2013551, https:\/\/doi.org\/10.1002\/ana.25570.","DOI":"10.1002\/ana.25570"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_145","doi-asserted-by":"crossref","unstructured":"McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R.Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., et al.. (2011). The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7: 263\u2013269, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_146","doi-asserted-by":"crossref","unstructured":"Melino, S., Santone, C., Di Nardo, P., and Sarkar, B. (2014). Histatins: salivary peptides with copper(II)- and zinc(II)-binding motifs: perspectives for biomedical applications. FEBS J. 281: 657\u2013672, https:\/\/doi.org\/10.1111\/febs.12612.","DOI":"10.1111\/febs.12612"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_147","doi-asserted-by":"crossref","unstructured":"Mesa-Herrera, F., Marin, R., Torrealba, E., Santos, G., and Diaz, M. (2022). Neuronal ER-signalosome proteins as early biomarkers in prodromal Alzheimer\u2019s disease independent of amyloid-beta production and tau phosphorylation. Front. Mol. Neurosci. 15: 879146, https:\/\/doi.org\/10.3389\/fnmol.2022.879146.","DOI":"10.3389\/fnmol.2022.879146"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_148","doi-asserted-by":"crossref","unstructured":"Meyne, F., Gloeckner, S.F., Ciesielczyk, B., Heinemann, U., Krasnianski, A., Meissner, B., and Zerr, I. (2009). Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J.\u00a0Alzheimers Dis. 17: 863\u2013873, https:\/\/doi.org\/10.3233\/jad-2009-1110.","DOI":"10.3233\/JAD-2009-1110"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_149","doi-asserted-by":"crossref","unstructured":"Minthon, L., Edvinsson, L., and Gustafson, L. (1996). Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 10: 197\u2013203, https:\/\/doi.org\/10.1097\/00002093-199601040-00005.","DOI":"10.1097\/00002093-199601040-00005"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_150","doi-asserted-by":"crossref","unstructured":"Mitsukawa, T., Takemura, J., Asai, J., Nakazato, M., Kangawa, K., Matsuo, H., and Matsukura, S. (1990). Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 39: 639\u2013642, https:\/\/doi.org\/10.2337\/diab.39.5.639.","DOI":"10.2337\/diab.39.5.639"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_151","doi-asserted-by":"crossref","unstructured":"Mohamed, W.A., Salama, R.M., and Schaalan, M.F. (2019). A pilot study on the effect of lactoferrin on Alzheimer\u2019s disease pathological sequelae: impact of the p-Akt\/PTEN pathway. Biomed. Pharmacother. 111: 714\u2013723, https:\/\/doi.org\/10.1016\/j.biopha.2018.12.118.","DOI":"10.1016\/j.biopha.2018.12.118"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_152","doi-asserted-by":"crossref","unstructured":"Moir, R.D., Lathe, R., and Tanzi, R.E. (2018). The antimicrobial protection hypothesis of Alzheimer\u2019s disease. Alzheimers Dement. 14: 1602\u20131614, https:\/\/doi.org\/10.1016\/j.jalz.2018.06.3040.","DOI":"10.1016\/j.jalz.2018.06.3040"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_153","doi-asserted-by":"crossref","unstructured":"Moore, C.X. and Cooper, G.J. (1991). Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem. Biophys. Res. Commun. 179: 1\u20139, https:\/\/doi.org\/10.1016\/0006-291x(91)91325-7.","DOI":"10.1016\/0006-291X(91)91325-7"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_154","doi-asserted-by":"crossref","unstructured":"Moulahoum, H., Ghorbani Zamani, F., Timur, S., and Zihnioglu, F. (2020). Metal binding antimicrobial peptides in nanoparticle bio-functionalization: new heights in drug delivery and therapy. Probiotics Antimicrob. Proteins 12: 48\u201363, https:\/\/doi.org\/10.1007\/s12602-019-09546-5.","DOI":"10.1007\/s12602-019-09546-5"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_155","doi-asserted-by":"crossref","unstructured":"Myhre, O., Utkilen, H., Duale, N., Brunborg, G., and Hofer, T. (2013). Metal dyshomeostasis and inflammation in Alzheimer\u2019s and Parkinson\u2019s diseases: possible impact of environmental exposures. Oxid. Med. Cell. Longev. 2013: 726954, https:\/\/doi.org\/10.1155\/2013\/726954.","DOI":"10.1155\/2013\/726954"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_156","doi-asserted-by":"crossref","unstructured":"Niemantsverdriet, E., Valckx, S., Bjerke, M., and Engelborghs, S. (2017). Alzheimer\u2019s disease CSF biomarkers: clinical indications and rational use. Acta Neurol. Belg. 117: 591\u2013602, https:\/\/doi.org\/10.1007\/s13760-017-0816-5.","DOI":"10.1007\/s13760-017-0816-5"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_157","doi-asserted-by":"crossref","unstructured":"Nijakowski, K., Owecki, W., Jankowski, J., and Surdacka, A. (2024). Salivary biomarkers for Alzheimer\u2019s disease: a systematic review with meta-analysis. Int. J.\u00a0Mol. Sci. 25, https:\/\/doi.org\/10.3390\/ijms25021168.","DOI":"10.3390\/ijms25021168"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_158","doi-asserted-by":"crossref","unstructured":"Noble, J.M., Scarmeas, N., and Papapanou, P.N. (2013). Poor oral health as a chronic, potentially modifiable dementia risk factor: review of the literature. Curr. Neurol. Neurosci. Rep. 13: 384, https:\/\/doi.org\/10.1007\/s11910-013-0384-x.","DOI":"10.1007\/s11910-013-0384-x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_159","doi-asserted-by":"crossref","unstructured":"Nuding, S., Gersemann, M., Hosaka, Y., Konietzny, S., Schaefer, C., Beisner, J., Schroeder, B.O., Ostaff, M.J., Saigenji, K., Ott, G., et al.. (2013). Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance. PLoS One 8: e73867, https:\/\/doi.org\/10.1371\/journal.pone.0073867.","DOI":"10.1371\/journal.pone.0073867"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_160","doi-asserted-by":"crossref","unstructured":"Nutt, J.G., Mrox, E.A., Leeman, S.E., Williams, A.C., Engel, W.K., and Chase, T.N. (1980). Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction. Neurology 30: 1280\u20131285, https:\/\/doi.org\/10.1212\/wnl.30.12.1280.","DOI":"10.1212\/WNL.30.12.1280"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_161","doi-asserted-by":"crossref","unstructured":"Oppenheim, F.G., Xu, T., McMillian, F.M., Levitz, S.M., Diamond, R.D., Offner, G.D., and Troxler, R.F. (1988). Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J.\u00a0Biol. Chem. 263: 7472\u20137477, https:\/\/doi.org\/10.1016\/s0021-9258(18)68522-9.","DOI":"10.1016\/S0021-9258(18)68522-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_162","doi-asserted-by":"crossref","unstructured":"Oren, Z., Lerman, J.C., Gudmundsson, G.H., Agerberth, B., and Shai, Y. (1999). Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 341: 501\u2013513, https:\/\/doi.org\/10.1042\/bj3410501.","DOI":"10.1042\/bj3410501"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_163","doi-asserted-by":"crossref","unstructured":"Oskarsson, M.E., Paulsson, J.F., Schultz, S.W., Ingelsson, M., Westermark, P., and Westermark, G.T. (2015). In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am. J.\u00a0Pathol. 185: 834\u2013846, https:\/\/doi.org\/10.1016\/j.ajpath.2014.11.016.","DOI":"10.1016\/j.ajpath.2014.11.016"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_164","doi-asserted-by":"crossref","unstructured":"Pain, S., Vergote, J., Gulhan, Z., Bodard, S., Chalon, S., and Gaillard, A. (2019). Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y. Fundam. Clin. Pharmacol. 33: 544\u2013548, https:\/\/doi.org\/10.1111\/fcp.12464.","DOI":"10.1111\/fcp.12464"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_165","doi-asserted-by":"crossref","unstructured":"Palmer, M.S., Dryden, A.J., Hughes, J.T., and Collinge, J. (1991). Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352: 340\u2013342, https:\/\/doi.org\/10.1038\/352340a0.","DOI":"10.1038\/352340a0"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_166","doi-asserted-by":"crossref","unstructured":"Pane, K., Sgambati, V., Zanfardino, A., Smaldone, G., Cafaro, V., Angrisano, T., Pedone, E., Di Gaetano, S., Capasso, D., Haney, E.F., et al.. (2016). A new cryptic cationic antimicrobial peptide from human apolipoprotein E with antibacterial activity and immunomodulatory effects on human cells. FEBS J. 283: 2115\u20132131, https:\/\/doi.org\/10.1111\/febs.13725.","DOI":"10.1111\/febs.13725"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_167","doi-asserted-by":"crossref","unstructured":"Park, M.S., Kim, J.I., Lee, I., Park, S., Bae, J.Y., and Park, M.S. (2018). Towards the application of human defensins as antivirals. Biomol. Ther. (Seoul) 26: 242\u2013254, https:\/\/doi.org\/10.4062\/biomolther.2017.172.","DOI":"10.4062\/biomolther.2017.172"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_168","doi-asserted-by":"crossref","unstructured":"Park, S.C., Moon, J.C., Shin, S.Y., Son, H., Jung, Y.J., Kim, N.H., Kim, Y.M., Jang, M.K., and Lee, J.R. (2016). Functional characterization of alpha-synuclein protein with antimicrobial activity. Biochem. Biophys. Res. Commun. 478: 924\u2013928, https:\/\/doi.org\/10.1016\/j.bbrc.2016.08.052.","DOI":"10.1016\/j.bbrc.2016.08.052"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_169","doi-asserted-by":"crossref","unstructured":"Parker, R.M. and Herzog, H. (1999). Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J.\u00a0Neurosci. 11: 1431\u20131448, https:\/\/doi.org\/10.1046\/j.1460-9568.1999.00553.x.","DOI":"10.1046\/j.1460-9568.1999.00553.x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_170","doi-asserted-by":"crossref","unstructured":"Parkin, E.T., Watt, N.T., Hussain, I., Eckman, E.A., Eckman, C.B., Manson, J.C., Baybutt, H.N., Turner, A.J., and Hooper, N.M. (2007). Cellular prion protein regulates beta-secretase cleavage of the Alzheimer\u2019s amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 104: 11062\u201311067, https:\/\/doi.org\/10.1073\/pnas.0609621104.","DOI":"10.1073\/pnas.0609621104"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_171","doi-asserted-by":"crossref","unstructured":"Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., and Calabresi, P. (2019). CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 18: 573\u2013586, https:\/\/doi.org\/10.1016\/s1474-4422(19)30024-9.","DOI":"10.1016\/S1474-4422(19)30024-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_172","doi-asserted-by":"crossref","unstructured":"Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Ritchie, K., Rossor, M., Thal, L., and Winblad, B. (2001). Current concepts in mild cognitive impairment. Arch. Neurol. 58: 1985\u20131992, https:\/\/doi.org\/10.1001\/archneur.58.12.1985.","DOI":"10.1001\/archneur.58.12.1985"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_173","doi-asserted-by":"crossref","unstructured":"Pezzoli, G., Panerai, A.E., Di Giulio, A., Longo, A., Passerini, D., and Carenzi, A. (1984). Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology 34: 516\u2013519, https:\/\/doi.org\/10.1212\/wnl.34.4.516.","DOI":"10.1212\/WNL.34.4.516"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_174","doi-asserted-by":"crossref","unstructured":"Poleggi, A., Bizzarro, A., Acciarri, A., Antuono, P., Bagnoli, S., Cellini, E., Forno, G.D., Giannattasio, C., Lauria, A., Matera, M.G., et al.. (2008). Codon 129 polymorphism of prion protein gene in sporadic Alzheimer\u2019s disease. Eur. J.\u00a0Neurol. 15: 173\u2013178, https:\/\/doi.org\/10.1111\/j.1468-1331.2007.02021.x.","DOI":"10.1111\/j.1468-1331.2007.02021.x"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_175","doi-asserted-by":"crossref","unstructured":"Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A.E., et al.. (2015). MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30: 1591\u20131601, https:\/\/doi.org\/10.1002\/mds.26424.","DOI":"10.1002\/mds.26424"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_176","doi-asserted-by":"crossref","unstructured":"Proto, C., Romualdi, D., Cento, R.M., Spada, R.S., Di Mento, G., Ferri, R., and Lanzone, A. (2006). Plasma levels of neuropeptides in Alzheimer\u2019s disease. Gynecol. Endocrinol. 22: 213\u2013218, https:\/\/doi.org\/10.1080\/09513590500519385.","DOI":"10.1080\/09513590500519385"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_177","doi-asserted-by":"crossref","unstructured":"Qiu, W.Q., Au, R., Zhu, H., Wallack, M., Liebson, E., Li, H., Rosenzweig, J., Mwamburi, M., and Stern, R.A. (2014a). Positive association between plasma amylin and cognition in a homebound elderly population. J.\u00a0Alzheimers Dis. 42: 555\u2013563, https:\/\/doi.org\/10.3233\/jad-140210.","DOI":"10.3233\/JAD-140210"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_178","doi-asserted-by":"crossref","unstructured":"Qiu, W.Q., Li, H., Zhu, H., Scott, T., Mwamburi, M., Rosenberg, I., and Rosenzweig, J. (2014b). Plasma amylin and cognition in diabetes in the absence and the presence of insulin treatment. J.\u00a0Diabetes Metab. 5, https:\/\/doi.org\/10.4172\/2155-6156.1000458.","DOI":"10.4172\/2155-6156.1000458"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_179","doi-asserted-by":"crossref","unstructured":"Qiu, W.Q., Wallack, M., Dean, M., Liebson, E., Mwamburi, M., and Zhu, H. (2014c). Association between amylin and amyloid-beta peptides in plasma in the context of apolipoprotein E4 allele. PLoS One 9: e88063, https:\/\/doi.org\/10.1371\/journal.pone.0088063.","DOI":"10.1371\/journal.pone.0088063"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_180","doi-asserted-by":"crossref","unstructured":"Quigley, B.J.Jr. and Kowall, N.W. (1991). Substance P-like immunoreactive neurons are depleted in Alzheimer\u2019s disease cerebral cortex. Neuroscience 41: 41\u201360, https:\/\/doi.org\/10.1016\/0306-4522(91)90199-x.","DOI":"10.1016\/0306-4522(91)90199-X"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_181","unstructured":"Qureshi, G.A., Baig, S.M., and Parvez, S.H. (2000). Variation in cerebrospinal fluid levels of neuropeptide Y, cholecystokinin and substance P in patients with neurological disorders. Neuro Endocrinol. Lett. 21: 409\u2013416."},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_182","doi-asserted-by":"crossref","unstructured":"Raha, A.A., Ghaffari, S.D., Henderson, J., Chakraborty, S., Allinson, K., Friedland, R.P., Holland, A., Zaman, S.H., Mukaetova-Ladinska, E.B., and Raha-Chowdhury, R. (2021). Hepcidin increases cytokines in Alzheimer\u2019s disease and down\u2019s syndrome dementia: implication of impaired iron homeostasis in neuroinflammation. Front. Aging Neurosci. 13: 653591, https:\/\/doi.org\/10.3389\/fnagi.2021.653591.","DOI":"10.3389\/fnagi.2021.653591"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_183","doi-asserted-by":"crossref","unstructured":"Raha, A.A., Vaishnav, R.A., Friedland, R.P., Bomford, A., and Raha-Chowdhury, R. (2013). The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer\u2019s disease. Acta Neuropathol. Commun. 1: 55, https:\/\/doi.org\/10.1186\/2051-5960-1-55.","DOI":"10.1186\/2051-5960-1-55"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_184","doi-asserted-by":"crossref","unstructured":"Raimundo, A.F., Ferreira, S., Martins, I.C., and Menezes, R. (2020). Islet amyloid polypeptide: a partner in crime with abeta in the pathology of Alzheimer\u2019s disease. Front. Mol. Neurosci. 13: 35, https:\/\/doi.org\/10.3389\/fnmol.2020.00035.","DOI":"10.3389\/fnmol.2020.00035"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_185","doi-asserted-by":"crossref","unstructured":"Reseco, L., Atienza, M., Fernandez-Alvarez, M., Carro, E., and Cantero, J.L. (2021). Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimers Res. Ther. 13: 150, https:\/\/doi.org\/10.1186\/s13195-021-00891-8.","DOI":"10.1186\/s13195-021-00891-8"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_186","doi-asserted-by":"crossref","unstructured":"Riemenschneider, M., Klopp, N., Xiang, W., Wagenpfeil, S., Vollmert, C., Muller, U., Forstl, H., Illig, T., Kretzschmar, H., and Kurz, A. (2004). Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 63: 364\u2013366, https:\/\/doi.org\/10.1212\/01.wnl.0000130198.72589.69.","DOI":"10.1212\/01.WNL.0000130198.72589.69"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_187","doi-asserted-by":"crossref","unstructured":"Rose, J.B., Crews, L., Rockenstein, E., Adame, A., Mante, M., Hersh, L.B., Gage, F.H., Spencer, B., Potkar, R., Marr, R.A., et al.. (2009). Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer\u2019s disease. J.\u00a0Neurosci. 29: 1115\u20131125, https:\/\/doi.org\/10.1523\/jneurosci.4220-08.2009.","DOI":"10.1523\/JNEUROSCI.4220-08.2009"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_188","doi-asserted-by":"crossref","unstructured":"Rosler, N., Wichart, I., and Jellinger, K.A. (2001a). Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer\u2019s disease patients. J.\u00a0Neural Transm. (Vienna) 108: 231\u2013246, https:\/\/doi.org\/10.1007\/s007020170091.","DOI":"10.1007\/s007020170091"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_189","doi-asserted-by":"crossref","unstructured":"Rosler, N., Wichart, I., and Jellinger, K.A. (2001b). Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer\u2019s disease patients. Neurosci. Lett. 299: 117\u2013120, https:\/\/doi.org\/10.1016\/s0304-3940(01)01514-2.","DOI":"10.1016\/S0304-3940(01)01514-2"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_190","doi-asserted-by":"crossref","unstructured":"Roth, J.D. (2013). Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. Curr. Opin. Endocrinol. Diabetes Obes. 20: 8\u201313, https:\/\/doi.org\/10.1097\/med.0b013e32835b896f.","DOI":"10.1097\/MED.0b013e32835b896f"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_191","doi-asserted-by":"crossref","unstructured":"Rushworth, J.V., Griffiths, H.H., Watt, N.T., and Hooper, N.M. (2013). Prion protein-mediated toxicity of amyloid-beta oligomers requires lipid rafts and the transmembrane LRP1. J.\u00a0Biol. Chem. 288: 8935\u20138951, https:\/\/doi.org\/10.1074\/jbc.m112.400358.","DOI":"10.1074\/jbc.M112.400358"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_192","doi-asserted-by":"crossref","unstructured":"Ryan, L.K., Dai, J., Yin, Z., Megjugorac, N., Uhlhorn, V., Yim, S., Schwartz, K.D., Abrahams, J.M., Diamond, G., and Fitzgerald-Bocarsly, P. (2011). Modulation of human beta-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity. J.\u00a0Leukoc. Biol. 90: 343\u2013356, https:\/\/doi.org\/10.1189\/jlb.0209079.","DOI":"10.1189\/jlb.0209079"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_193","doi-asserted-by":"crossref","unstructured":"Sabatini, L.M. and Azen, E.A. (1989). Histatins, a family of salivary histidine-rich proteins, are encoded by at least two loci (HIS1 and HIS2). Biochem. Biophys. Res. Commun. 160: 495\u2013502, https:\/\/doi.org\/10.1016\/0006-291x(89)92460-1.","DOI":"10.1016\/0006-291X(89)92460-1"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_194","doi-asserted-by":"crossref","unstructured":"Saeed, U., Compagnone, J., Aviv, R.I., Strafella, A.P., Black, S.E., Lang, A.E., and Masellis, M. (2017). Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: current and emerging concepts. Transl. Neurodegener. 6: 8, https:\/\/doi.org\/10.1186\/s40035-017-0076-6.","DOI":"10.1186\/s40035-017-0076-6"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_195","doi-asserted-by":"crossref","unstructured":"Sanchez-Gomez, A., Alcarraz-Vizan, G., Fernandez, M., Fernandez-Santiago, R., Ezquerra, M., Camara, A., Serrano, M., Novials, A., Munoz, E., Valldeoriola, F., et al.. (2020). Peripheral insulin and amylin levels in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 79: 91\u201396, https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.018.","DOI":"10.1016\/j.parkreldis.2020.08.018"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_196","doi-asserted-by":"crossref","unstructured":"Santos, J., Gracia, P., Navarro, S., Pena-Diaz, S., Pujols, J., Cremades, N., Pallares, I., and Ventura, S. (2021). alpha-Helical peptidic scaffolds to target alpha-synuclein toxic species with nanomolar affinity. Nat. Commun. 12: 3752, https:\/\/doi.org\/10.1038\/s41467-021-24039-2.","DOI":"10.1038\/s41467-021-24039-2"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_269","doi-asserted-by":"crossref","unstructured":"Schirinzi, T., Maftei, D., Ralli, M., Greco, A., Mercuri, N. B., Lattanzi, R., and Severini, C. (2021). Serum substance P is increased in Parkinson\u2019s disease and correlates with motor impairment. Mov. Disord. 37: 228\u2013230, https:\/\/doi.org\/10.1002\/mds.28824.","DOI":"10.1002\/mds.28824"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_197","doi-asserted-by":"crossref","unstructured":"Schittek, B. (2012). The multiple facets of dermcidin in cell survival and host defense. J.\u00a0Innate Immun. 4: 349\u2013360, https:\/\/doi.org\/10.1159\/000336844.","DOI":"10.1159\/000336844"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_198","doi-asserted-by":"crossref","unstructured":"Schittek, B., Hipfel, R., Sauer, B., Bauer, J., Kalbacher, H., Stevanovic, S., Schirle, M., Schroeder, K., Blin, N., Meier, F., et al.. (2001). Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat. Immunol. 2: 1133\u20131137, https:\/\/doi.org\/10.1038\/ni732.","DOI":"10.1038\/ni732"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_199","doi-asserted-by":"crossref","unstructured":"Schluesener, H. and Meyermann, R. (1995). Neutrophilic defensins penetrate the blood-brain barrier. J.\u00a0Neurosci. Res. 42: 718\u2013723, https:\/\/doi.org\/10.1002\/jnr.490420515.","DOI":"10.1002\/jnr.490420515"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_200","doi-asserted-by":"crossref","unstructured":"Schmidt, C., Artjomova, S., Hoeschel, M., and Zerr, I. (2013). CSF prion protein concentration and cognition in patients with Alzheimer disease. Prion 7: 229\u2013234, https:\/\/doi.org\/10.4161\/pri.23904.","DOI":"10.4161\/pri.23904"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_201","doi-asserted-by":"crossref","unstructured":"Schmidt, C., Becker, H., Peter, C., Lange, K., Friede, T., and Zerr, I. (2014). Plasma prion protein concentration and progression of Alzheimer disease. Prion 8, https:\/\/doi.org\/10.4161\/pri.27964.","DOI":"10.4161\/pri.27964"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_202","doi-asserted-by":"crossref","unstructured":"Schmitz, M., Hermann, P., Oikonomou, P., Stoeck, K., Ebert, E., Poliakova, T., Schmidt, C., Llorens, F., Zafar, S., and Zerr, I. (2015). Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. Neurobiol. Aging 36: 2597\u20132606, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.05.013.","DOI":"10.1016\/j.neurobiolaging.2015.05.013"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_203","doi-asserted-by":"crossref","unstructured":"Schneider, B., Baudry, A., Pietri, M., Alleaume-Butaux, A., Bizingre, C., Nioche, P., Kellermann, O., and Launay, J.M. (2021). The cellular prion protein-ROCK connection: contribution to neuronal homeostasis and neurodegenerative diseases. Front. Cell. Neurosci. 15: 660683, https:\/\/doi.org\/10.3389\/fncel.2021.660683.","DOI":"10.3389\/fncel.2021.660683"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_204","doi-asserted-by":"crossref","unstructured":"Schrag, A., Siddiqui, U.F., Anastasiou, Z., Weintraub, D., and Schott, J.M. (2017). Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol. 16: 66\u201375, https:\/\/doi.org\/10.1016\/s1474-4422(16)30328-3.","DOI":"10.1016\/S1474-4422(16)30328-3"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_205","doi-asserted-by":"crossref","unstructured":"Schroder, J.B., Marian, T., Claus, I., Muhle, P., Pawlowski, M., Wiendl, H., Suntrup-Krueger, S., Meuth, S.G., Dziewas, R., Ruck, T., et al.. (2019). Substance P saliva reduction predicts pharyngeal dysphagia in Parkinson\u2019s disease. Front. Neurol. 10: 386, https:\/\/doi.org\/10.3389\/fneur.2019.00386.","DOI":"10.3389\/fneur.2019.00386"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_206","doi-asserted-by":"crossref","unstructured":"Schultz, N., Janelidze, S., Byman, E., Minthon, L., Nagga, K., Hansson, O., and Wennstrom, M. (2019). Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer\u2019s disease. PLoS One 14: e0218561, https:\/\/doi.org\/10.1371\/journal.pone.0218561.","DOI":"10.1371\/journal.pone.0218561"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_207","doi-asserted-by":"crossref","unstructured":"Sepehri, A., Nepal, B., and Lazaridis, T. (2021). Distinct modes of action of IAPP oligomers on membranes. J.\u00a0Chem. Inf. Model. 61: 4645\u20134655, https:\/\/doi.org\/10.1021\/acs.jcim.1c00767.","DOI":"10.1021\/acs.jcim.1c00767"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_208","doi-asserted-by":"crossref","unstructured":"Sergi, D., Renaud, J., Simola, N., and Martinoli, M.G. (2019). Diabetes, a contemporary risk for Parkinson\u2019s disease: epidemiological and cellular evidences. Front. Aging Neurosci. 11: 302, https:\/\/doi.org\/10.3389\/fnagi.2019.00302.","DOI":"10.3389\/fnagi.2019.00302"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_209","doi-asserted-by":"crossref","unstructured":"Shimizu, M., Shigeri, Y., Tatsu, Y., Yoshikawa, S., and Yumoto, N. (1998). Enhancement of antimicrobial activity of neuropeptide Y by N-terminal truncation. Antimicrob. Agents Chemother. 42: 2745\u20132746, https:\/\/doi.org\/10.1128\/aac.42.10.2745.","DOI":"10.1128\/AAC.42.10.2745"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_210","doi-asserted-by":"crossref","unstructured":"Sood, R., Domanov, Y., Pietiainen, M., Kontinen, V.P., and Kinnunen, P.K. (2008). Binding of LL-37 to model biomembranes: insight into target vs. host cell recognition. Biochim. Biophys. Acta 1778: 983\u2013996, https:\/\/doi.org\/10.1016\/j.bbamem.2007.11.016.","DOI":"10.1016\/j.bbamem.2007.11.016"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_211","doi-asserted-by":"crossref","unstructured":"Sorensen, O., Arnljots, K., Cowland, J.B., Bainton, D.F., and Borregaard, N. (1997). The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90: 2796\u20132803, https:\/\/doi.org\/10.1182\/blood.v90.7.2796.2796_2796_2803.","DOI":"10.1182\/blood.V90.7.2796.2796_2796_2803"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_212","doi-asserted-by":"crossref","unstructured":"Soscia, S.J., Kirby, J.E., Washicosky, K.J., Tucker, S.M., Ingelsson, M., Hyman, B., Burton, M.A., Goldstein, L.E., Duong, S., Tanzi, R.E., et al.. (2010). The Alzheimer\u2019s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5: e9505, https:\/\/doi.org\/10.1371\/journal.pone.0009505.","DOI":"10.1371\/journal.pone.0009505"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_213","doi-asserted-by":"crossref","unstructured":"Spencer, B., Potkar, R., Metcalf, J., Thrin, I., Adame, A., Rockenstein, E., and Masliah, E. (2016). Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of alzheimer disease. J.\u00a0Biol. Chem. 291: 1905\u20131920, https:\/\/doi.org\/10.1074\/jbc.m115.678185.","DOI":"10.1074\/jbc.M115.678185"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_214","doi-asserted-by":"crossref","unstructured":"Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R.Jr., Kaye, J., Montine, T.J., et al.. (2011). Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7: 280\u2013292, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_215","doi-asserted-by":"crossref","unstructured":"Sternberg, Z., Hu, Z., Sternberg, D., Waseh, S., Quinn, J.F., Wild, K., Jeffrey, K., Zhao, L., and Garrick, M. (2017). Serum hepcidin levels, iron dyshomeostasis and cognitive loss in Alzheimer\u2019s disease. Aging Dis. 8: 215\u2013227, https:\/\/doi.org\/10.14336\/ad.2016.0811.","DOI":"10.14336\/AD.2016.0811"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_216","doi-asserted-by":"crossref","unstructured":"Stoeck, K., Schmitz, M., Ebert, E., Schmidt, C., and Zerr, I. (2014). Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer\u2019s disease and multiple sclerosis. J.\u00a0Neuroinflamm. 11: 170, https:\/\/doi.org\/10.1186\/s12974-014-0170-y.","DOI":"10.1186\/s12974-014-0170-y"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_217","doi-asserted-by":"crossref","unstructured":"Sunderland, T., Berrettini, W.H., Molchan, S.E., Lawlor, B.A., Martinez, R.A., Vitiello, B., Tariot, P.N., and Cohen, R.M. (1991). Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer\u2019s disease. Biol. Psychiatry 30: 81\u201387, https:\/\/doi.org\/10.1016\/0006-3223(91)90073-u.","DOI":"10.1016\/0006-3223(91)90073-U"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_218","doi-asserted-by":"crossref","unstructured":"Svenningsson, P., Palhagen, S., and Mathe, A.A. (2017). Neuropeptide Y and calcitonin gene-related peptide in cerebrospinal fluid in Parkinson\u2019s disease with comorbid depression versus patients with major depressive disorder. Front. Psychiatry 8: 102, https:\/\/doi.org\/10.3389\/fpsyt.2017.00102.","DOI":"10.3389\/fpsyt.2017.00102"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_219","doi-asserted-by":"crossref","unstructured":"Szekeres, M., Ivitz, E., Datki, Z., Kalman, J., Pakaski, M., Varhelyi, Z.P., Klivenyi, P., Zadori, D., Somogyvari, F., Szolnoki, Z., et al.. (2016). Relevance of defensin beta-2 and alpha defensins (HNP1-3) in Alzheimer\u2019s disease. Psychiatry Res. 239: 342\u2013345, https:\/\/doi.org\/10.1016\/j.psychres.2016.03.045.","DOI":"10.1016\/j.psychres.2016.03.045"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_220","doi-asserted-by":"crossref","unstructured":"Takeuchi, Y., Nagasawa, T., Katagiri, S., Kitagawara, S., Kobayashi, H., Koyanagi, T., and Izumi, Y. (2012). Salivary levels of antibacterial peptide (LL-37\/hCAP-18) and cotinine in patients with chronic periodontitis. J.\u00a0Periodontol. 83: 766\u2013772, https:\/\/doi.org\/10.1902\/jop.2011.100767.","DOI":"10.1902\/jop.2011.100767"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_221","doi-asserted-by":"crossref","unstructured":"Tang, Y., Zhang, D., Gong, X., and Zheng, J. (2022). Repurposing of intestinal defensins as multi-target, dual-function amyloid inhibitors via cross-seeding. Chem. Sci. 13: 7143\u20137156, https:\/\/doi.org\/10.1039\/d2sc01447e.","DOI":"10.1039\/D2SC01447E"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_222","doi-asserted-by":"crossref","unstructured":"Thome, J., Gsell, W., Rosler, M., Kornhuber, J., Frolich, L., Hashimoto, E., Zielke, B., Wiesbeck, G.A., and Riederer, P. (1997). Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer\u2019s disease. Life Sci. 60: 13\u201319, https:\/\/doi.org\/10.1016\/s0024-3205(96)00583-8.","DOI":"10.1016\/S0024-3205(96)00583-8"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_223","doi-asserted-by":"crossref","unstructured":"Thome, J., Munch, G., Muller, R., Schinzel, R., Kornhuber, J., Blum-Degen, D., Sitzmann, L., Rosler, M., Heidland, A., and Riederer, P. (1996). Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer\u2019s disease. Life Sci. 59: 679\u2013685, https:\/\/doi.org\/10.1016\/0024-3205(96)00349-9.","DOI":"10.1016\/0024-3205(96)00349-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_224","doi-asserted-by":"crossref","unstructured":"Tiszlavicz, Z., Endresz, V., Nemeth, B., Megyeri, K., Orosz, L., Seprenyi, G., and Mandi, Y. (2011). Inducible expression of human beta-defensin 2 by Chlamydophila pneumoniae in brain capillary endothelial cells. Innate Immun. 17: 463\u2013469, https:\/\/doi.org\/10.1177\/1753425910375582.","DOI":"10.1177\/1753425910375582"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_225","doi-asserted-by":"crossref","unstructured":"Torres, P., Castro, M., Reyes, M., and Torres, V.A. (2018). Histatins, wound healing, and cell migration. Oral Dis. 24: 1150\u20131160, https:\/\/doi.org\/10.1111\/odi.12816.","DOI":"10.1111\/odi.12816"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_226","doi-asserted-by":"crossref","unstructured":"Troxler, R.F., Offner, G.D., Xu, T., Vanderspek, J.C., and Oppenheim, F.G. (1990). Structural relationship between human salivary histatins. J.\u00a0Dent. Res. 69: 2\u20136, https:\/\/doi.org\/10.1177\/00220345900690010101.","DOI":"10.1177\/00220345900690010101"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_227","doi-asserted-by":"crossref","unstructured":"Turkoglu, O., Emingil, G., Kutukculer, N., and Atilla, G. (2009). Gingival crevicular fluid levels of cathelicidin LL-37 and interleukin-18 in patients with chronic periodontitis. J.\u00a0Periodontol. 80: 969\u2013976, https:\/\/doi.org\/10.1902\/jop.2009.080532.","DOI":"10.1902\/jop.2009.080532"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_228","doi-asserted-by":"crossref","unstructured":"Ubink, R. and Hokfelt, T. (2000). Expression of neuropeptide Y in olfactory ensheathing cells during prenatal development. J.\u00a0Comp. Neurol. 423: 13\u201325, https:\/\/doi.org\/10.1002\/1096-9861(20000717)423:1<13::aid-cne2>3.0.co;2-p.","DOI":"10.1002\/1096-9861(20000717)423:1<13::AID-CNE2>3.0.CO;2-P"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_229","doi-asserted-by":"crossref","unstructured":"Urosevic, N. and Martins, R.N. (2008). Infection and Alzheimer\u2019s disease: the APOE epsilon4 connection and lipid metabolism. J.\u00a0Alzheimers Dis. 13: 421\u2013435, https:\/\/doi.org\/10.3233\/jad-2008-13407.","DOI":"10.3233\/JAD-2008-13407"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_230","doi-asserted-by":"crossref","unstructured":"Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N.P., Arredondo, M., Gonzalez-Billault, C., and Nunez, M.T. (2013). Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J.\u00a0Neurochem. 126: 541\u2013549, https:\/\/doi.org\/10.1111\/jnc.12244.","DOI":"10.1111\/jnc.12244"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_231","doi-asserted-by":"crossref","unstructured":"Urrutia, P.J., Hirsch, E.C., Gonzalez-Billault, C., and Nunez, M.T. (2017). Hepcidin attenuates amyloid beta-induced inflammatory and pro-oxidant responses in astrocytes and microglia. J.\u00a0Neurochem. 142: 140\u2013152, https:\/\/doi.org\/10.1111\/jnc.14005.","DOI":"10.1111\/jnc.14005"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_232","unstructured":"vanderSpek, J.C., Wyandt, H.E., Skare, J.C., Milunsky, A., Oppenheim, F.G., and Troxler, R.F. (1989). Localization of the genes for histatins to human chromosome 4q13 and tissue distribution of the mRNAs. Am. J.\u00a0Hum. Genet. 45: 381\u2013387."},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_233","doi-asserted-by":"crossref","unstructured":"Verma, N., Velmurugan, G.V., Winford, E., Coburn, H., Kotiya, D., Leibold, N., Radulescu, L., Despa, S., Chen, K.C., Van Eldik, L.J., et al.. (2023). Abeta efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas. Commun. Biol. 6: 2, https:\/\/doi.org\/10.1038\/s42003-022-04398-2.","DOI":"10.1038\/s42003-022-04398-2"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_234","doi-asserted-by":"crossref","unstructured":"Voigtlander, T., Kloppel, S., Birner, P., Jarius, C., Flicker, H., Verghese-Nikolakaki, S., Sklaviadis, T., Guentchev, M., and Budka, H. (2001). Marked increase of neuronal prion protein immunoreactivity in Alzheimer\u2019s disease and human prion diseases. Acta Neuropathol. 101: 417\u2013423, https:\/\/doi.org\/10.1007\/s004010100405.","DOI":"10.1007\/s004010100405"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_235","doi-asserted-by":"crossref","unstructured":"Wang, L., Liu, Q., Chen, J.C., Cui, Y.X., Zhou, B., Chen, Y.X., Zhao, Y.F., and Li, Y.M. (2012). Antimicrobial activity of human islet amyloid polypeptides: an insight into amyloid peptides\u2019 connection with antimicrobial peptides. Biol. Chem. 393: 641\u2013646, https:\/\/doi.org\/10.1515\/hsz-2012-0107.","DOI":"10.1515\/hsz-2012-0107"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_236","doi-asserted-by":"crossref","unstructured":"Wang, M., Peng, I.F., Li, S., and Hu, X. (2020). Dysregulation of antimicrobial peptide expression distinguishes Alzheimer\u2019s disease from normal aging. Aging (Albany NY) 12: 690\u2013706, https:\/\/doi.org\/10.18632\/aging.102650.","DOI":"10.18632\/aging.102650"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_237","doi-asserted-by":"crossref","unstructured":"Wang, J., Song, N., Jiang, H., Wang, J., and Xie, J. (2013). Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen\/nitrogen species production in ventral mesencephalic neurons. Biochim. Biophys. Acta 1832: 618\u2013625, https:\/\/doi.org\/10.1016\/j.bbadis.2013.01.021.","DOI":"10.1016\/j.bbadis.2013.01.021"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_238","doi-asserted-by":"crossref","unstructured":"Waters, C.M., Peck, R., Rossor, M., Reynolds, G.P., and Hunt, S.P. (1988). Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson\u2019s disease and Huntington\u2019s chorea. Neuroscience 25: 419\u2013438, https:\/\/doi.org\/10.1016\/0306-4522(88)90249-7.","DOI":"10.1016\/0306-4522(88)90249-7"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_239","doi-asserted-by":"crossref","unstructured":"Watt, A.D., Perez, K.A., Ang, C.S., O\u2019Donnell, P., Rembach, A., Pertile, K.K., Rumble, R.L., Trounson, B.O., Fowler, C.J., Faux, N.G., et al.. (2015). Peripheral alpha-defensins 1 and 2 are elevated in Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 44: 1131\u20131143, https:\/\/doi.org\/10.3233\/jad-142286.","DOI":"10.3233\/JAD-142286"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_240","doi-asserted-by":"crossref","unstructured":"Welling, M.M., Nabuurs, R.J., and van der Weerd, L. (2015). Potential role of antimicrobial peptides in the early onset of Alzheimer\u2019s disease. Alzheimers Dement. 11: 51\u201357, https:\/\/doi.org\/10.1016\/j.jalz.2013.12.020.","DOI":"10.1016\/j.jalz.2013.12.020"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_241","doi-asserted-by":"crossref","unstructured":"Whitehouse, I.J., Jackson, C., Turner, A.J., and Hooper, N.M. (2010). Prion protein is reduced in aging and in sporadic but not in familial Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 22: 1023\u20131031, https:\/\/doi.org\/10.3233\/jad-2010-101071.","DOI":"10.3233\/JAD-2010-101071"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_242","doi-asserted-by":"crossref","unstructured":"Whitehouse, I.J., Miners, J.S., Glennon, E.B., Kehoe, P.G., Love, S., Kellett, K.A., and Hooper, N.M. (2013). Prion protein is decreased in Alzheimer\u2019s brain and inversely correlates with BACE1 activity, amyloid-beta levels and Braak stage. PLoS One 8: e59554, https:\/\/doi.org\/10.1371\/journal.pone.0059554.","DOI":"10.1371\/journal.pone.0059554"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_243","doi-asserted-by":"crossref","unstructured":"Williams, W.M., Castellani, R.J., Weinberg, A., Perry, G., and Smith, M.A. (2012). Do beta-defensins and other antimicrobial peptides play a role in neuroimmune function and neurodegeneration? Sci. World J. 2012: 905785, https:\/\/doi.org\/10.1100\/2012\/905785.","DOI":"10.1100\/2012\/905785"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_244","doi-asserted-by":"crossref","unstructured":"Williams, W.M., Torres, S., Siedlak, S.L., Castellani, R.J., Perry, G., Smith, M.A., and Zhu, X. (2013). Antimicrobial peptide beta-defensin-1 expression is upregulated in Alzheimer\u2019s brain. J.\u00a0Neuroinflamm. 10: 127, https:\/\/doi.org\/10.1186\/1742-2094-10-127.","DOI":"10.1186\/1742-2094-10-127"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_245","doi-asserted-by":"crossref","unstructured":"Wogulis, M., Wright, S., Cunningham, D., Chilcote, T., Powell, K., and Rydel, R.E. (2005). Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J.\u00a0Neurosci. 25: 1071\u20131080, https:\/\/doi.org\/10.1523\/jneurosci.2381-04.2005.","DOI":"10.1523\/JNEUROSCI.2381-04.2005"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_246","doi-asserted-by":"crossref","unstructured":"Xu, X., Cai, X., Zhu, Y., He, W., Wu, Q., Shi, X., Fang, Y., and Pei, Z. (2018). MFG-E8 inhibits Abeta-induced microglial production of cathelicidin-related antimicrobial peptide: a suitable target against Alzheimer\u2019s disease. Cell. Immunol. 331: 59\u201366, https:\/\/doi.org\/10.1016\/j.cellimm.2018.05.008.","DOI":"10.1016\/j.cellimm.2018.05.008"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_247","doi-asserted-by":"crossref","unstructured":"Xu, T., Levitz, S.M., Diamond, R.D., and Oppenheim, F.G. (1991). Anticandidal activity of major human salivary histatins. Infect. Immun. 59: 2549\u20132554, https:\/\/doi.org\/10.1128\/iai.59.8.2549-2554.1991.","DOI":"10.1128\/iai.59.8.2549-2554.1991"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_248","doi-asserted-by":"crossref","unstructured":"Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., and Chen, H. (2011). Diabetes and risk of Parkinson\u2019s disease. Diabetes Care 34: 910\u2013915, https:\/\/doi.org\/10.2337\/dc10-1922.","DOI":"10.2337\/dc10-1922"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_249","doi-asserted-by":"crossref","unstructured":"Xu, S.F., Zhang, Y.H., Wang, S., Pang, Z.Q., Fan, Y.G., Li, J.Y., Wang, Z.Y., and Guo, C. (2019). Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice. Redox Biol. 21: 101090, https:\/\/doi.org\/10.1016\/j.redox.2018.101090.","DOI":"10.1016\/j.redox.2018.101090"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_250","doi-asserted-by":"crossref","unstructured":"Xu, Y., Zhang, Y., Zhang, J.H., Han, K., Zhang, X., Bai, X., You, L.H., Yu, P., Shi, Z., Chang, Y.Z., et al.. (2020). Astrocyte hepcidin ameliorates neuronal loss through attenuating brain iron deposition and oxidative stress in APP\/PS1 mice. Free Radic. Biol. Med. 158: 84\u201395, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.07.012.","DOI":"10.1016\/j.freeradbiomed.2020.07.012"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_251","unstructured":"Yaksh, T.L., Carmichael, S.W., Stoddard, S.L., Tyce, G.M., Kelly, P.J., Lucas, D., van Heerden, J.A., Ahlskog, J.E., and Byer, D.E. (1990). Measurement of lumbar CSF levels of met-enkephalin, encrypted met-enkephalin, and neuropeptide Y in normal patients and in patients with Parkinson\u2019s disease before and after autologous transplantation of adrenal medulla into the caudate nucleus. J.\u00a0Lab. Clin. Med. 115: 346\u2013351."},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_252","doi-asserted-by":"crossref","unstructured":"Yang, Y.W., Hsieh, T.F., Li, C.I., Liu, C.S., Lin, W.Y., Chiang, J.H., Li, T.C., and Lin, C.C. (2017). Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore) 96: e5921, https:\/\/doi.org\/10.1097\/md.0000000000005921.","DOI":"10.1097\/MD.0000000000005921"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_253","doi-asserted-by":"crossref","unstructured":"Yong, S.J., Veerakumarasivam, A., Lim, W.L., and Chew, J. (2023). Neuroprotective effects of lactoferrin in Alzheimer\u2019s and Parkinson\u2019s diseases: a narrative review. ACS Chem. Neurosci. 14: 1342\u20131355, https:\/\/doi.org\/10.1021\/acschemneuro.2c00679.","DOI":"10.1021\/acschemneuro.2c00679"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_254","doi-asserted-by":"crossref","unstructured":"Yong, S.J., Yong, M.H., Teoh, S.L., Soga, T., Parhar, I., Chew, J., and Lim, W.L. (2021). The hippocampal vulnerability to herpes simplex virus type I infection: relevance to Alzheimer\u2019s disease and memory impairment. Front. Cell. Neurosci. 15, https:\/\/doi.org\/10.3389\/fncel.2021.695738.","DOI":"10.3389\/fncel.2021.695738"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_255","doi-asserted-by":"crossref","unstructured":"Young, P.N.E., Estarellas, M., Coomans, E., Srikrishna, M., Beaumont, H., Maass, A., Venkataraman, A.V., Lissaman, R., Jimenez, D., Betts, M.J., et al.. (2020). Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res. Ther. 12: 49, https:\/\/doi.org\/10.1186\/s13195-020-00612-7.","DOI":"10.1186\/s13195-020-00612-7"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_256","doi-asserted-by":"crossref","unstructured":"Yu, S.Y., Sun, L., Liu, Z., Huang, X.Y., Zuo, L.J., Cao, C.J., Zhang, W., and Wang, X.M. (2013). Sleep disorders in Parkinson\u2019s disease: clinical features, iron metabolism and related mechanism. PLoS One 8: e82924, https:\/\/doi.org\/10.1371\/journal.pone.0082924.","DOI":"10.1371\/journal.pone.0082924"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_257","doi-asserted-by":"crossref","unstructured":"Zalewska, A., Klimiuk, A., Zieba, S., Wnorowska, O., Rusak, M., Waszkiewicz, N., Szarmach, I., Dzierzanowski, K., and Maciejczyk, M. (2021). Salivary gland dysfunction and salivary redox imbalance in patients with Alzheimer\u2019s disease. Sci. Rep. 11: 23904, https:\/\/doi.org\/10.1038\/s41598-021-03456-9.","DOI":"10.1038\/s41598-021-03456-9"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_258","doi-asserted-by":"crossref","unstructured":"Zech, M. and Bogerts, B. (1985). Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. Acta Neuropathol. 68: 32\u201338, https:\/\/doi.org\/10.1007\/bf00688953.","DOI":"10.1007\/BF00688953"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_259","doi-asserted-by":"crossref","unstructured":"Zhang, J., Goodlett, D.R., Quinn, J.F., Peskind, E., Kaye, J.A., Zhou, Y., Pan, C., Yi, E., Eng, J., Wang, Q., et al.. (2005). Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J.\u00a0Alzheimers Dis. 7: 125\u2013133; discussion 173\u2013180, https:\/\/doi.org\/10.3233\/jad-2005-7205.","DOI":"10.3233\/JAD-2005-7205"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_260","doi-asserted-by":"crossref","unstructured":"Zhang, X., Gou, Y.J., Zhang, Y., Li, J., Han, K., Xu, Y., Li, H., You, L.H., Yu, P., Chang, Y.Z., et al.. (2020). Hepcidin overexpression in astrocytes alters brain iron metabolism and protects against amyloid-beta induced brain damage in mice. Cell Death Discov. 6: 113, https:\/\/doi.org\/10.1038\/s41420-020-00346-3.","DOI":"10.1038\/s41420-020-00346-3"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_261","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, Y., Tang, Y., Zhang, D., He, H., Wu, J., and Zheng, J. (2021). Antimicrobial alpha-defensins as multi-target inhibitors against amyloid formation and microbial infection. Chem. Sci. 12: 9124\u20139139, https:\/\/doi.org\/10.1039\/d1sc01133b.","DOI":"10.1039\/D1SC01133B"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_262","doi-asserted-by":"crossref","unstructured":"Zhang, W.J., Shang, X.L., Peng, J., Zhou, M.H., and Sun, W.J. (2017). Expression of prion protein in the cerebrospinal fluid of patients with Parkinson\u2019s disease complicated with rapid eye movement sleep behavior disorder. Genet. Mol. Res. 16, https:\/\/doi.org\/10.4238\/gmr16019022.","DOI":"10.4238\/gmr16019022"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_263","doi-asserted-by":"crossref","unstructured":"Zhang, L.Y., Wang, D.Z., Wang, J., Guo, L., Li, B.H., and Wang, J.H. (2023). Associations of serum antimicrobial peptide LL-37 with longitudinal cognitive decline and neurodegeneration among older adults with memory complaints. J.\u00a0Alzheimers Dis. 93: 595\u2013603, https:\/\/doi.org\/10.3233\/jad-230007.","DOI":"10.3233\/JAD-230007"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_264","doi-asserted-by":"crossref","unstructured":"Zhu, H., Tao, Q., Ang, T.F.A., Massaro, J., Gan, Q., Salim, S., Zhu, R.Y., Kolachalama, V.B., Zhang, X., Devine, S., et al.. (2019). Association of plasma amylin concentration with Alzheimer disease and brain structure in older adults. JAMA Netw. Open 2: e199826, https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.9826.","DOI":"10.1001\/jamanetworkopen.2019.9826"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_265","doi-asserted-by":"crossref","unstructured":"Zhu, H., Wang, X., Wallack, M., Li, H., Carreras, I., Dedeoglu, A., Hur, J.Y., Zheng, H., Li, H., Fine, R., et al.. (2015). Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer\u2019s disease. Mol. Psychiatry 20: 252\u2013262, https:\/\/doi.org\/10.1038\/mp.2014.17.","DOI":"10.1038\/mp.2014.17"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_266","doi-asserted-by":"crossref","unstructured":"Zhu, H., Xue, X., Wang, E., Wallack, M., Na, H., Hooker, J.M., Kowall, N., Tao, Q., Stein, T.D., Wolozin, B., et al.. (2017). Amylin receptor ligands reduce the pathological cascade of Alzheimer\u2019s disease. Neuropharmacology 119: 170\u2013181, https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.030.","DOI":"10.1016\/j.neuropharm.2017.03.030"},{"key":"2025121816130083970_j_revneuro-2025-0034_ref_267","doi-asserted-by":"crossref","unstructured":"Zuo, L.J., Yu, S.Y., Hu, Y., Wang, F., Piao, Y.S., Lian, T.H., Yu, Q.J., Wang, R.D., Li, L.X., Guo, P., et al.. (2016). Serotonergic dysfunctions and abnormal iron metabolism: relevant to mental fatigue of Parkinson disease. Sci. Rep. 6: 19, https:\/\/doi.org\/10.1038\/s41598-016-0018-z.","DOI":"10.1038\/s41598-016-0018-z"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2025-0034\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2025-0034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:14:57Z","timestamp":1766074497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2025-0034\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":269,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,12,17]]}},"alternative-id":["10.1515\/revneuro-2025-0034"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2025-0034","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}